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Appendix  
_____________________________________________________________________________ 
Chapter 4 Delphi Process 
 
Dear      , 
  
I am doing a PhD entitled "Making trials matter: providing an empirical basis for the promotion (or 
rejection) of pragmatic design choices in clinical trials".  You cited the Thorpe KE, Zwarenstein M, 
Oxman AD, et al. paper entitled "A pragmatic-explanatory continuum indicator summary (PRECIS): a 
tool to help trial designers." in your paper “Name, Title, Reference” and I wondered whether you 
would be interested in helping us with this research.  
  
We have received funding from the Chief Scientist Office in Scotland to undertake further work on 
PRECIS, and I am writing to ask for your help with the first phase of the project.  
The first phase starts in October and would involve answering a Survey Monkey questionnaire on 
PRECIS that would take about 10 minutes to complete. If you complete the survey and let us know 
your name we will acknowledge your input in future publications. 
https://www.surveymonkey.com/s/PRagmaticExplanatoryContinuumIndicatorSummaries.   
  
If you are interested in participating in a further round of Survey monkey we would be grateful for 
your help. In addition, you may also be interested in assisting with further phases of the project to 
validate to PRECIS, all data will be anonymised. The second phase (December to April 2013) is one to 
one or group testing of different PRECIS models using a topic guide. This would entail participants 
answering questions on the PRECIS domains (looking at different aspect of trial design), scoring and 
structure of the proposed PRECIS models. This could take up to 1 hour at sessions in London Ontario 
in Canada or at the University of Dundee in Scotland.  We would like to audio record the sessions, to 
assist in analysis, unless participants do not give consent. There is limited funding available for UK 
participants to attend meetings in Dundee.  
  
Finally, the third phase, would involve using the modified PRECIS model, PRECIS 2, to score a sample 
of 15 trials over a two month period by e-mail.  We can provide some funding for raters involved in 
Phase 3 work. All participation is strictly voluntary and you can leave at any stage in the project. If 
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you are interested in participating in any of the phases do get in touch or let me know when 
completing this section in the Survey Monkey questionnaire. Feel free to pass on this e-mail to 
anybody you think might be interested in participating in the project. 
  
If you require further information please do not hesitate to get in touch. My e-mail address is: 
 k.loudon@dundee.ac.uk 
  
We hope you will consider helping us with this important research on clinical trial design and look 
forward to hearing from you at your earliest convenience. 
  
 
Kirsty Loudon (PhD Student), University of Dundee 
  
On behalf of Shaun Treweek, Frank Sullivan, Merrick Zwarenstein, Peter Donnan  
(PhD Supervisors and co-applicants on CSO grant CZH/4/773 MAKING CLINICAL TRIALS MORE RELEVANT: 
IMPROVING AND VALIDATING THE PRECIS TOOL FOR MATCHING TRIAL DESIGN DECISIONS TO TRIAL PURPOSE) 
  
 
The University of Dundee is a registered Scottish Charity, No: SC015096 
Box 4.1 Example Invitation e-mail with title: PRECIS – PRagmatic Explanatory Continuum 
Indicator Summaries 
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Chapter 5 Brainstorming – first meeting 
 
Subject: PRECIS brainstorming session (PRagmatic Explanatory Continuum Indicator 
Summary) trial design tool 
 
Hi, 
  
I started a PhD in October, supervised by Shaun Treweek, Frank Sullivan and Merrick Zwarenstein, 
looking at pragmatic trials, in particular validating a tool to help trialists design pragmatic trials, 
called PRECIS. I believe PRECIS could be very useful for designing real world trials that are useful 
to clinicians and policymakers.   
  
I am writing to invite you to join a brainstorming meeting to discuss trial design and the PRECIS 
tool.  Participants would be from Dundee University and we would meet at the Mackenzie Building.  
The group would run from 1pm to 3pm, with lunch available from 12.30.  Our provisional date for 
the meeting is Friday 8th June although we can change this.  I have attached a training package 
for PRECIS to give you some information about the tool and how it was used with two example 
trials. I have also attached the original article describing PRECIS which gives further information: 
Thorpe et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial 
designers. Journal of Clinical Epidemiology 2009; 62: 464-475.  
 
If you can attend please let me know and I will then send two short trials that I would like to 
discuss at the meeting so that I can get some input into developing the tool.  
 
I would be very grateful for any time and help you can give to this project and look forward to 
hearing whether or not you will be able to attend.   
  
Best wishes 
  
Kirsty 
  
Contact details: 
Division of Population Health Sciences 
University of Dundee 
Kirsty Semple Way 
Dundee DD2 4BF 
UK 
  
Email: K.Loudon@dundee.ac.uk 
Skype: kirsty3 
Mob: 0779 694 7551 
 
Box 5.1 Invitation to attend first brainstorming meeting in Dundee with local participants 
 
 
4 
 
Box 5.2 Agenda for first brainstorming meeting, Dundee 8
th
 June 2012. 
Agenda Friday 8
th
 June 1-3pm 2012 
1. Introductions:  
a. KL and ST 
b. Audio transcript – introductions for everyone in the room (first, last name and department) 
2. What did group think about PRECIS? First impressions using PRECIS  
3. Brief discussion about tool, why are we doing this – improve PRECIS  - KL 
4. Jolly example – ST - discuss   
5. Price example – KL- discuss  
6. Questions ( topic guide of questions but include: domains missed out, not necessary, scoring, weighting, 
strengths/weaknesses, difficulty in scoring, anything else) 
7. Close 
 
 
5 
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From: Kirstine Loudon  
Sent: 12th November 2012 10.51 
To: 
Subject: PRECIS - PRagmatic Explanatory Continuum Indicator Summaries 
 
Dear X, 
 
I am doing a PhD entitled "Making trials matter: providing an empirical basis for the promotion (or 
rejection) of pragmatic design choices in clinical trials" and I wondered whether you would be 
interested in helping us with this research by attending a meeting in March 2013 in London, 
Ontario or Toronto. 
 
We would like to discuss results from a modified Delphi carried out in October and November 
2012 and proposed modifications of the original PRECIS model. This would entail participants 
discussing the PRECIS domains (looking at different aspect of trial design), scoring and structure of 
possible PRECIS models. This could take up to 2 hours at sessions in London Ontario in Canada or 
Toronto in Canada.  Funding is limited, so if you would like to attend you would need to use your 
own travel and accommodation budget. We are currently uncertain if we can fund full 
videoconferencing for the meetings. If you can attend, please let me know which destination suits 
you best: London, Ontario or Toronto? I have set up a Doodle poll with possible dates in March so 
would be grateful if you would click on this link and or feel free to respond to this e-mail 
http://www.doodle.com/4g5fcgk9vpt5eh29 by Monday 19th November. 
                                                                        
If you require further information please do not hesitate to get in touch. My e-mail address is: 
 k.loudon@dundee.ac.uk 
 
We hope you will consider helping us with this important research on clinical trial design and look 
forward to hearing from you at your earliest convenience. 
 
Best wishes 
 
 
Kirsty Loudon (PhD Student), University of Dundee 
 
On behalf of Shaun Treweek, Merrick Zwarenstein, Frank Sullivan, Peter Donnan  
(PhD Supervisors and co-applicants on CSO grant CZH/4/773 MAKING CLINICAL TRIALS MORE RELEVANT: 
IMPROVING AND VALIDATING THE PRECIS TOOL FOR MATCHING TRIAL DESIGN DECISIONS TO TRIAL PURPOSE) 
 
 
 
Kirsty Loudon 
 
PhD student, University of Dundee 
 
Contact details: 
Division of Population Health Sciences 
 
 
7 
 
Brainstorming – second meeting  
Box 5.3 Invitation to attend second brainstorming meeting in Toronto who had not been 
involved in the modified Delphi 
 
University of Dundee 
Kirsty Semple Way 
Dundee DD2 4BF 
UK 
 
Email: K.Loudon@dundee.ac.uk 
Skype: kirsty3 
Tel 01382 383779 
Mob: 0779 694 7551 
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From: Kirstine Loudon  
Sent: Fri 11/01/2013 12:11 
To: 'Daniel L Riddle' <dlriddle@vcu.edu>; 'Moher, David' <dmoher@ohri.ca>; 'Krishnan, Jerry' 
<jakris@uic.edu>; louis.fiore@va.gov; vivian.welch@uottawa.ca; Joel Gagnier PhD 
(jgagnier@med.umich.edu); kevin.thorpe@utoronto.ca; anwen.chan@utoronto.ca; 
rob.fowler@sunnybrook.ca; malcolm.maclure@ubc.ca; 'Kent, David' 
dkent1@tuftsmedicalcenter.org 
CC: 'gallardo@uic.edu'; murray.krahn@theta.utoronto.ca; merrick.zwarenstein@ices.on.ca; 'Lutz, 
Jennifer S' <Jlutz@tuftsmedicalcenter.org>; Shaun Treweek <streweek@mac.com> 
Subject: Pragmatic Trials - PRECIS meeting Monday 11th March 9.30-5pm Toronto, Canada 
 
 
Happy New Year! 
  
We are going ahead with Monday 11th March 9.30-5pm. I am delighted that the meeting is being 
hosted by Murray Krahn, Professor, Department of Medicine and Faculty of Pharmacy, University 
of Toronto Director and being held at THETA, F. 144 College Street, Rm 600, Toronto ON, M5S 
3M2. 
  
Could you please confirm you are still able to attend, there will probably be 14 of us: Dan Riddle, 
David Moher, Jerry Krishnan, Lou Fiore, Vivian Welch, Joel Gagnier, Kevin Thorpe, An When Chan, 
possibly Rob Fowler, David Kent, and Malcolm Maclure, as well as Merrick Zwarenstein, my PhD 
supervisor who is helping facilitate the meeting, our host Murray Krahn and me.   
  
We are uncertain at present if we will have web conferencing. 
 
DRAFT PRECIS Meeting Agenda 
1.       Present Chief Scientist Office (CSO) grant project on PRECIS – Pragmatic Explanatory 
Continuum Indicator Summaries - 4 phases 
2.       Results from Phase 1 on PRECIS project, modified DELPHI 2 rounds carried out in October 
and November 2012 
3.       Phase 2 - Presentation of Modified PRECIS models prepared based on Round 1 results  
4.       Discussion on models – audiotaped if ok with everyone at meeting. 
            Participants discuss the PRECIS domains (looking at different aspect of trial design), 
scoring and structure of possible PRECIS models. 
Break for lunch 
Afternoon discussion 
• new approach to significance testing for pragmatic trials 
or 
• plan a PRECIS elaboration paper, a detailed paper that picks out each of the 
assertions or ideas for PRECIS and gathers the evidence. 
 
I look forward to hearing if you can join us. Funding is limited, so if you would like to attend you 
would need to use your own travel and accommodation budget but THETA is kindly providing 
refreshments and lunch will be provided. CSO will also pay for taxis to and from the airport. 
  
For those out of town, suggestions for accommodation close to THETA are: 
•        Madison Manor Boutique Hotel - Toronto, Ontario Canada 
http://madisonmanorboutiquehotel.com/ which has a good reputation, just a few yards 
north of Bloor street. Also about 15 minutes walk and one subway stop away the meeting 
venue.  
•        The Holiday Inn 
http://www.holidayinn.com/hotels/us/en/toronto/yyzct/hoteldetail/directions, on Bloor 
 
 
9 
 
street between st georges street and spadine avenue- also one subway stop or about 15 
minutes walk from the meeting venue  
•         Primrose Hotel http://www.torontoprimrosehotel.com/contact/directions 
  
Any questions do get in touch. Maps are attached.  
 
Best wishes 
  
Kirsty 
  
Kirsty Loudon 
  
PhD student, University of Dundee 
  
Contact details: 
Division of Population Health Sciences 
University of Dundee 
Kirsty Semple Way 
Dundee DD2 4BF 
UK 
  
Email: K.Loudon@dundee.ac.uk 
Skype: kirsty3 
Tel +44 1382 383779 
Mob: +44 779 694 7551 
  
 
The University of Dundee is a registered Scottish Charity, No: SC015096  
 
Box 5.4 Confirmation Invitation with Agenda for second brainstorming meeting in Toronto  
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From: Joanna Bielecki <joanna.bielecki@theta.utoronto.ca> 
Sent: 5th March 2013 15.13 
To: Eric.S.Johnson@kpchr.org; powersjohn@mail.nih.gov; Peter_Selby@camh.net; 
Noemilois@aol.com; jsegal@jhsph.edu; Janet.Martin@lhsc.on.ca; Kirstine Loudon 
<k.loudon@dundee.ac.uk> 
Subject: TRIAL: for video-conferencing PRECIS Meeting in Toronto 
 
Hello Everyone, 
 
I am one of the organizers of PRECIS Meeting in Toronto, and in charge of the technical support 
for video-conferencing portion of the meeting. I would like to invite you to a trial video-
conference meeting on Thursday, March 7th, 2013. I will be sending official invitations to this trial 
meeting tomorrow, with full instructions on how to connect and test your system. The trial will 
run as a continuous meeting, you would be able to connect to the trial at any time between 10am 
- 5pm EST. This will be an opportunity for you to test your local systems configuration and 
connectivity before the March 11th PRECIS conference in Toronto; so that if any problems arise 
you will have a chance to consult your local IT support and correct the problems. I hope this will 
be helpful to avoid any technical delays on the day of the PRECIS conference. 
 
Best wishes and hope to hear from you on March 7th. 
  
Joanna Bielecki 
Research Librarian 
 
Toronto Health Economics and Technology Assessment Collaborative (THETA) 
Leslie Dan Pharmacy, University of Toronto 
144 College Street, 6th Floor Room 679 
Toronto, ON M5S 3M2 
joanna.bielecki@theta.utoronto.ca 
416-946-0583 
theta.utoronto.ca 
 
Box 5.5 Invitation to attend video conferencing at second brainstorming meeting in 
Toronto  
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Third Brainstorming meeting 
From: Kirstine Loudon  
Sent: 12 April 2013 12:04 
To: Peter Donnan; Shaun Treweek; Roberta Littleford; Thomas Lamont; Frank Sullivan, Fiona 
Hogwarth 
Subject: PhD assistance with domains for PRECIS-2 - tool to improve the applicability of RCTs 
  
Hi, 
I would like to have further input to improving the PRECIS tool following the Delphi results and a 
meeting in Toronto with a group of methodologists, statisticians, policy makers and doctors.   
  
Back in June last year I appreciated input from you Peter, Thomas, Fiona and unfortunately you 
were unable to attend Roberta. I wondered if you would be available for an hour Monday 22nd 
April at for instance 1pm with Frank and Shaun my PhD supervisors to meet at the Mackenzie 
building? So checking availability for you all, if not then would later in the day be better 2.30/3pm 
after a meeting on the Tonsillectomy trial you are having with Roberta, Frank? 
  
I look forward to hearing from you and if not would Tuesday 23rd or Monday 29th April be better?  
  
Best wishes 
  
Kirsty 
  
Kirsty Loudon 
  
PhD student, University of Dundee 
  
Contact details: 
Division of Population Health Sciences 
University of Dundee 
Kirsty Semple Way 
Dundee DD2 4BF 
UK 
  
Email: K.Loudon@dundee.ac.uk 
Skype: kirsty3 
Tel 01382 383779 
Mob: 0779 694 7551 
  
 
The University of Dundee is a registered Scottish Charity, No: SC015096 
 
Box 5.6 Reminder to attend third brainstorming meeting in Dundee 
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From: Kirstine Loudon 
Sent: 26 April 2013 17:05 
To: Roberta Littleford; Shaun Treweek; Frank Sullivan; Peter Donnan; Thomas Lamont 
Subject: Reminder: PhD assistance with domains for PRECIS-2 - tool to improve the applicability 
of RCTs 
  
Hi, 
Apologies for the late reminder. Just to confirm I look forward to seeing you on Monday 29th April 
12.30-2pm at the Mackenzie building, we are downstairs in CTA.  As it is over lunch, I have 
ordered some sandwiches and coffee. 
  
Greatly appreciate your help and I look forward to seeing you for any or all of the time we have 
the meeting room booked. 
  
Have a good weekend. 
  
Best wishes 
  
Kirsty 
  
  
Kirsty Loudon 
  
PhD student, University of Dundee 
  
Contact details: 
Division of Population Health Sciences 
University of Dundee 
Kirsty Semple Way 
Dundee DD2 4BF 
UK 
  
Email: K.Loudon@dundee.ac.uk 
Skype: kirsty3 
Tel 01382 383779 
Mob: 0779 694 7551 
 
Box 5.7 Reminder to attend third brainstorming meeting in Dundee 
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Post Brainstorming prior to user testing 
 
We recommend that trialists or others assessing whether design decisions are fit for purpose, do 
this iteratively using six steps:  
1. Describe the purpose of the trial: [choosing between options, revealing expected benefits.  
2. Specify the settings and participants to which the findings of the trial are applicable, and the 
organizational changes, resources and training to be added to conduct the trial.  
3. Specify the design options at the pragmatic and explanatory extremes of each domain  
4. Consider your trial design choices for each domain.  
5. Score these choices according to how pragmatic or explanatory each is in relation to the 
extremes for each domain and make a mark between pragmatic and explanatory on the wheel 
spoke for 'score 1-5' or ‘score 1-7’. 
6. Review design choices (5) against purpose (1) and decide whether your trial design decisions 
match your intended purpose. Modify and re-iterate if required. 
NB: To avoid confusion in terminology, we have carefully split the participants involved in clinical 
trials into intervention-care recipients and intervention-care delivery participants.  
Box 5.8 PRECIS 2 training instructions for PRECIS-2 
 
Box 5.9 Key PRECIS-2 difference 
 
•Recruitment path  
•Setting  
•Similarity between the resources, provider expertise and the organisation of care delivery, in the 
intervention arm of the trial.  
•Similarity between the resources, provider expertise and the organisation of care delivery, in the 
comparison arm of the trial  
 
Box 5.10 PRECIS-2 DOMAIN differences 
 
1.To improve trial Generalisability of 
Results  
 
Now have at beginning of each 
domain: 
 “The similarity between…DOMAIN…  
 
And at the end of each domain: 
in the setting to which the results will be 
applied.”  
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CONSENT FORM - Participant’s copy 
 
  
Title of Project: MAKING CLINICAL TRIALS MORE RELEVANT: IMPROVING AND VALIDATING THE 
PRECIS TOOL FOR MATCHING TRIAL DESIGN DECISIONS TO TRIAL PURPOSE 
 
Name of Researcher: Kirsty Loudon 
 
 
Put a 
tick in 
1 
I confirm that I have understood the information given to me for this study. 
I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily.  
 
2 
I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason  
3 I give my permission for the discussion to be audio recorded.  
4 
I understand that the notes and transcripts of the discussion may be looked 
at by individuals from the University of Dundee (the Sponsor of the 
 
5 
I agree to take part in the above study. 
 
 
_______________________  _____________________ ___________________ 
Name of participant   Date     Signature 
_______________________  ______________________ ___________________ 
Name of person taking consent               Date     Signature 
Box 6.2 Participant Consent form  
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Chapter 7 – Validity and Reliability study 
 
Dear  , 
As you may recall, I am doing a PhD entitled "Making trials matter: providing an empirical basis for 
the promotion (or rejection) of pragmatic design choices in clinical trials. Previously you indicated 
you would be interested in helping us with the third phase of this research funded by the Chief 
Scientist Office in Scotland. 
 
We are building on the work to develop the PRECIS (PRagmatic Explanatory Continuum Indicator 
Summaries) tool to design clinical trials that are more relevant. The protocol was published in 
April (Making clinical trials more relevant: improving and validating the PRECIS tool for matching 
trial design decisions to trial purpose Trials, 14:115.) 
  
We would like you to use the modified PRECIS model, PRECIS-2, to score a sample of 15 trial 
protocols over a two month period.  PRECIS-2 has been developed using a Delphi survey, 
brainstorming through meetings in Toronto and Dundee and user testing with an international 
group of trialists and researchers.  
 
Can you please confirm that you are still interested in assisting?  We can provide payment if you 
help us with this Phase 3 work of approximately $160  (£100) depending on how many people 
agree to take part. As soon as you confirm your interest, I will send out a batch of five trial 
protocols every two weeks, with a 3 page PRECIS-2 user guide and a PRECIS-2 wheel and table for 
you to use to score each protocol.  
 
If you require further information please do not hesitate to get in touch. My e-mail address is: 
k.loudon@dundee.ac.uk 
 
We really hope you will help us with this important research on clinical trial design and look 
forward to hearing from you at your earliest convenience. 
 
Kirsty Loudon (PhD Student), University of Dundee 
On behalf of Shaun Treweek, Frank Sullivan, Merrick Zwarenstein, Peter Donnan  
(PhD Supervisors and co-applicants on CSO grant CZH/4/773 MAKING CLINICAL TRIALS MORE 
RELEVANT: IMPROVING AND VALIDATING THE PRECIS TOOL FOR MATCHING TRIAL DESIGN 
DECISIONS TO TRIAL PURPOSE) 
 
 
Box 7.1 Example invitation e-mail with title: Invitation to participate in the validity and 
reliability testing of PRECIS-2 
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Hi, 
Just sending a quick reminder to encourage you to help validate PRECIS-2.  
 
 As I believe Shaun mentioned, this would involve using the modified PRECIS model, 
PRECIS-2, to score a sample of 15 trials over a 6 week period, so by 1st November.  I am 
hoping you can do all 15 but it would be a great help if you could do 5 or 10 depending on 
time. So far testers are returning saying taking “less than the 20mins per protocol” so 
hope that you can get back to me soon. 
 
 Please score the protocols using the PRECIS-2 wheel or using the table with a 1-5 Likert 
score (5 being very pragmatic, 1 very explanatory).  If using the wheel, feel free to write 
notes on the paper, take a copy, and send to me in Dundee or scan in and e-mail me - 
Kirsty. If scoring using the table, and think there is some uncertainty, please jot down 
rationale.  
 
I look forward to hearing from you, with your scores for the 5 protocols. I will then send 
you another batch of 5 protocols if you can continue to help with this work. Don’t hesitate 
to get in touch if you have any questions. 
 
Thank you for your interest in the project. 
Best wishes 
 
Kirsty 
 
Box 7.2 Example of deadline reminder e-mail with title: PRECIS-2 validation work 5 
protocols
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Chapter 7C Validity and reliability raw results with sensitivity analysis  
ELIGIBILITY 
 
Results 1 
Sample:  5 trial protocols, 18 raters 
 4 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis, 3 not done due to time and 1 due to lack of expertise in the area 
(physiotherapist). Imputed values 4/90 = 4.4% of data 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .455
a
 .196 .881 16.041 4 68 .000 
Average Measures .938 .814 .993 16.041 4 68 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
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Results 2 
10 trials, 12 raters 
2 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis, both not done due to lack 
of expertise in the area (physiotherapist) – one rater missed out whole trial as not area of expertise (not just 
domain). Imputed values 2/120 = 1.67% of data. 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .405
a
 .205 .716 9.177 9 99 .000 
Average Measures .891 .755 .968 9.177 9 99 .000 
 
Results 3 
Sample 15 trials, 7 raters 
 
1 imputed value at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis, 1 not done due to lack of 
expertise in the area (physiotherapist). Imputed values 1/135 = 0.74% of data. 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .506
a
 .302 .741 8.157 14 84 .000 
Average Measures .877 .752 .952 8.157 14 84 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance.  
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Missing data Eligibility criteria 
 
Rater Info. Protocol Rationale quote from rater 
2. Did not do 11, 12, 13, 14, 15 due to time  
4 physiotherapist 4 “No entry, obviously no content knowledge on this one. Too far afield 
of my content to judge.” 
6 Did not do 11, 12, 13, 14, 15 due to time  
8 Did not do 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 due to 
time 
 
11. Kinesology, systematic 
reviewer 
Did not do 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 due 
to time 
 
12 Did not do 11, 12, 13, 14, 15 due to time. 7 as no 
expertise in area 
 
13 Did not do 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 due to 
time 
 
14 Did not do 11, 12, 13, 14, 15 due to time  
15 Did not do 7, 8, 9, 10, 11, 12, 13, 14, 15 due to 
time 
 
16 Did not do 11, 12, 13, 14, 15 due to time  
17. Did not do 2, 4, 9, 10, 11, 12, 13, 14, 15 due to 
time 
 
18. Did not do 1, 2, 3, 4, 11, 12, 13, 14, 15 due to 
time. 
 
19.  Did not do 11, 12, 13, 14, 15 due to time  
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RECRUITMENT 
 
Results 1 
Sample:  5 trial protocols, 18 raters 
 4 imputed values at 3 = equally pragmatic/explanatory. 1 due to “inadequate information” and 3 due to “lack of time”. Thus complete set for ICC analysis, 3 
not done due to time and 1 due to lack of expertise in the area (physiotherapist). Imputed values 4/90 = 4.4% of data. 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .214
a
 .052 .729 5.912 4 68 .000 
Average Measures .831 .496 .980 5.912 4 68 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
 
Results 2. 
Sample 10 trials, 12 raters 
2 imputed value at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis, 2 not done due to lack of expertise in the area (physiotherapist, 
medical doctor). Imputed values 2/120 = 1.67% of data. 
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Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .112
a
 .010 .386 2.509 9 99 .012 
Average Measures .601 .105 .883 2.509 9 99 .012 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Results 3 
Sample 15 trials, 7 raters 
1 imputed value at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis, 1 not done due to “lack of information”). Imputed values 1/135 = 
0.74% of data. 
First analysis 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .159
a
 .020 .416 2.321 14 84 .009 
Average Measures .569 .127 .833 2.321 14 84 .009 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
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Note for discussion:  
Rater 3 (Bridget Gaglio) results very different to everyone else: 1 compared to 5 for several trials (10, 11, 14, 15). Co-author with Russ Glasgow (trialists 
complex interventions) worked on trials using PRECIS-1, did 15 protocols within 2 weeks, experienced rater. When looked at rationale for rating – no 
information. She also stated when queried when results first submitted “if the information was not provided I scored it a one instead of guessing base on 
the other information in the protocol.  Thus PRECIS-2 score changed to “3” = equally pragmatic/explanatory so consistency across raters for issue of “lack of 
information”. 
 
Rater 7 (Marion Campbell), experienced trialists, also consistently higher than others – stated “standard recruitment path”. 
 
2
nd
 analysis 
 
Sample 15 trials, 7 raters 
5 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis, 5 due to lack of information in protocol. Imputed values 5/105 = 
4.76% of data 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .173
a
 .030 .433 2.460 14 84 .006 
Average Measures .594 .176 .842 2.460 14 84 .006 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
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Missing data Recruitment 
 
Rater Protocol Rationale quote from rater 
2. Did not do 11, 12, 13, 14, 15 due to time  
3 10 “No mention of how patients will be recruited” 
3 11 “no information on how participants were recruited at the various sites” 
3 14 “no information on how patients will be recruited only states type of patients 
included: informed consent will be obtained” 
3 15 “Unclear how patients are recruited for the study” 
4. physiotherapist 10 “content knowledge extremely critical to judge this one…)” 
5. 3, 9, 13 Unclear so gave “3” score 
6.  Did not do 11, 12, 13, 14, 15 due to time  
7 1, 2, 4, 5, 7, 9, 10, 11, 13, 14, 15 “Standard recruitment path” 
8 Did not do 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 
due to time 
 
11. Kinesology, systematic 
reviewer 
Did not do 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 
15 due to time 
 
12. Did not do 11, 12, 13, 14, 15 due to time. 7 
as no expertise in area 
 
13. Did not do 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 
due to time 
 
14 Did not do 11, 12, 13, 14, 15 due to time  
15. medical practitioner, 
trialist 
2 “inadequate information” 
15.  Did not do 7, 8, 9, 10, 11, 12, 13, 14, 15 
due to time 
 
16 Did not do 11, 12, 13, 14, 15 due to time  
17. Did not do 2, 4, 9, 10, 11, 12, 13, 14, 15 
due to time 
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Rater Protocol Rationale quote from rater 
18. Did not do 1, 2, 3, 4, 11, 12, 13, 14, 15 due 
to time. 
 
19. Did not do 11, 12, 13, 14, 15 due to time  
 
SETTING 
Results 1 
Sample:  5 trial protocols, 18 raters 
 4 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis, 3 not done due to time, 1 “unclear to judge”. Imputed values 
4/90 = 4.4% of data 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .386
a
 .149 .850 12.339 4 68 .000 
Average Measures .919 .758 .990 12.339 4 68 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
Results 2 
Sample 10 trials, 12 raters 
2 imputed value at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis, 1 not done due to insufficient information to judge, one entire 
protocol (not just domain) due to medical practitioners’s lack of knowledge in the trial area. Imputed values 2/120 = 1.67% of data. 
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Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .254
a
 .095 .576 5.086 9 99 .000 
Average Measures .803 .559 .942 5.086 9 99 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
Results 3 
Sample 15 trials, 7 raters 
1 imputed values at 3 = equally pragmatic/explanatory, not done as “unclear to judge”.  Thus complete set for ICC analysis. Imputed value 1/105 = 0.95% of 
data 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .371
a
 .179 .636 5.128 14 84 .000 
Average Measures .805 .605 .924 5.128 14 84 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
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Missing data for Setting 
Rater Protocol Rationale quote from rater 
2. Did not do 11, 12, 13, 14, 15 due to time  
3. 4 “It is unclear to me which are the recruitment and intervention centres, so I 
cannot say if there are referral special centres or not” 
4, clinician, trialists 4 “was u unclear to me what setting” 
 
6.  Did not do 11, 12, 13, 14, 15 due to time  
8 Did not do 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 
due to time 
 
11. Kinesology, 
systematic reviewer 
Did not do 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 
due to time 
 
12. Did not do 10, 11, 12, 13, 14, 15 due to 
time. 7 as no expertise in area 
 
13. Did not do 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 
due to time 
 
14 Did not do 11, 12, 13, 14, 15 due to time  
15.  Did not do 7, 8, 9, 10, 11, 12, 13, 14, 15 due 
to time 
 
16 Did not do 11, 12, 13, 14, 15 due to time  
17. Did not do 2, 4, 9, 10, 11, 12, 13, 14, 15 due 
to time 
 
18. Did not do 1, 2, 3, 4, 11, 12, 13, 14, 15 due 
to time. 
 
19. Did not do 11, 12, 13, 14, 15 due to time  
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Organisation 
 
Results 1 
Sample:  5 trial protocols, 18 raters 
There were six imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis. Three scores not done due to lack of time, one due 
to lack of expertise in the area (physiotherapist) and one as inadequate information, and 2 due to difficulty scoring . Imputed values 6/90 = 5.55% of data 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .142
a
 .018 .641 3.971 4 68 .006 
Average Measures .748 .249 .970 3.971 4 68 .006 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Results 2 
10 trials, 12 raters 
Imputed values at 3 = equally pragmatic/explanatory for 2 scores – 2 not done due to lack of expertise in the area (physiotherapist). One entire protocol (not 
just domain)was missed out due to medical practitioners’ lack of knowledge in the trial area and same rater thought “The new organisation domain is very 
complex” so missed out scoring 6 trials for the “Organisation” domain. Thus complete set for ICC analysis. Imputed values 9/120 = 7.5% of data 
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Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .286
a
 .117 .610 5.807 9 99 .000 
Average Measures .828 .613 .949 5.807 9 99 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Results 3 
Sample 15 trials, 7 raters 
2 imputed values at 3 = equally pragmatic/explanatory thus complete set for ICC analysis. Imputed values 2/105 = 1.90% of data 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .270
a
 .099 .541 3.584 14 84 .000 
Average Measures .721 .435 .892 3.584 14 84 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
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Missing data Organisation 
Rater Protocol Rationale quote from rater 
2. Did not do 11, 12, 13, 14, 15 due to time  
4. Physiotherapist Did not complete this domain in 4, 10  “Too far afield of my content to judge. Don’t know enough” 
5. Trialist Did not complete this domain in 15 “Unclear whether it is clearly different from routine care at 
those centers.” 
6. Did not do 11, 12, 13, 14, 15 due to time  
8.  Did not do 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 due to time  
11. Did not do 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 due to time  
12. medical practitioner, 
trialist 
Did not complete this domain in 4, 5, 6, 8, 9, 10 “The new organisation domain is very complex” 
12. medical practitioner, 
trialist 
Did not do 11, 12, 13, 14, 15 due to time. 7 as no 
expertise in area 
 
13. Did not do 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 due to time  
14 Did not do 11, 12, 13, 14, 15 due to time  
15. medical practitioner, 
trialist 
Did not complete this domain in 4 “was unclear to me what level of organization was to be used” 
15.  Did not do 7, 8, 9, 10, 11, 12, 13, 14, 15 due to time  
16 Did not do 11, 12, 13, 14, 15 due to time  
17. Did not do 2, 4, 9, 10, 11, 12, 13, 14, 15 due to time  
18. Did not do 1, 2, 3, 4, 11, 12, 13, 14, 15 due to time.  
19. Did not do 11, 12, 13, 14, 15 due to time  
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Flexibility of experimental intervention – Delivery 
 
Results 1 
Sample:  5 trial protocols, 18 raters 
There were six imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis. Three scores not done by same rater due to due to 
lack of expertise in the area (physiotherapist), three protocols due to time (2 raters).  Imputed values 6/90 = 6.67% of data 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .375
a
 .141 .844 11.804 4 68 .000 
Average Measures .915 .747 .990 11.804 4 68 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
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Results 2 
Sample: 10 trials, 12 raters 
There were 6 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis. Three scores not done by same rater due to due to 
lack of expertise in the area (physiotherapist), three protocols due to time (2 raters).  Imputed values 6/90 = 6.67% of data 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .325
a
 .144 .648 6.787 9 99 .000 
Average Measures .853 .669 .957 6.787 9 99 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Results 3 
Sample 15 trials, 7 raters 
There were 3 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis. Three scores not done by same rater due to due to 
lack of expertise in the area (physiotherapist). Imputed values 3/90 = 3.33% of data. 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .289
a
 .113 .560 3.839 14 84 .000 
Average Measures .740 .472 .899 3.839 14 84 .000 
Two-way random effects model where both people effects and measures effects are random. 
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a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Missing data Flexibility of experimental intervention – Delivery 
Rater Protocol Rationale quote from rater 
2. Did not do 11, 12, 13, 
14, 15 due to time 
 
4. Physiotherapist 4, 5, 10 “Too far afield of my content to judge. Don’t know enough”; “Just too difficult for me to judge given lack of 
understanding of usual care expectations” 
5. 5 “Standardised and inflexible CS procedures” 
6. Did not do 11, 12, 13, 
14, 15 due to time 
 
8.  Did not do 6, 7, 8, 9, 
10, 11, 12, 13, 14, 15 
due to time 
 
11 Did not do 2, 6, 7, 8, 
9, 10, 11, 12, 13, 14, 
15 due to time 
 
12 medical 
practitioner, trialist 
 It is still a problem if the trial compares two or more interventions (see my rating on Azuara-Blanco), which 
are different in flexibility, this needs guidance, furthermore information is needed how to handle adjunct 
treatment to usual care versus usual care only, is usual care only no intervention or also rated as 
intervention which would be always end up with 5 and might be totally different than the intervention, 
making it difficult to decide on a number between 1 and 5. 
 
12 medical 
practitioner, trialist 
Did not do 11, 12, 13, 
14, 15 due to time 
 
12 medical 
practitioner, trialist 
Did not do 7 “as not area of expertise” 
13. Did not do 6, 7, 8, 9, 
10, 11, 12, 13, 14, 15 
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Rater Protocol Rationale quote from rater 
due to time 
14 Did not do 11, 12, 13, 
14, 15 due to time 
 
15.  Did not do 7, 8, 9, 10, 
11, 12, 13, 14, 15 due 
to time 
 
16 Did not do 11, 12, 13, 
14, 15 due to time 
 
17. Did not do 2, 4, 9, 10, 
11, 12, 13, 14, 15 due 
to time 
 
18. Did not do 1, 2, 3, 4, 
11, 12, 13, 14, 15 due 
to time. 
 
19. Did not do 11, 12, 13, 
14, 15 due to time 
 
 
Flexibility of experimental intervention - Adherence 
 
Results 1 
Sample:  5 trial protocols, 18 raters 
There were EIGHTEEN imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis (see reasons below) mainly due to lack of 
information in protocol. Imputed values 14/90 = 15.56% of data 
 
 
Intraclass Correlation Coefficient 
 Intraclass 95% Confidence Interval F Test with True Value 0 
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Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .124
a
 .010 .613 3.542 4 68 .011 
Average Measures .718 .159 .966 3.542 4 68 .011 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Results 2 
Sample: 10 trials, 12 raters 
There were 4 + 4 + 4 + 2 +3 = 17 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis (see reasons below) mainly due to 
lack of information in protocol. Imputed values 17/108 = 15.74% of data 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .101
a
 .004 .368 2.343 9 99 .019 
Average Measures .573 .042 .875 2.343 9 99 .019 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
 
Results 3 
 
 
35 
 
Sample 15 trials, 7 raters 
There were eight imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis. Problems with rating arose due to one rater 
stating there was a lack of information in protocol and had no knowledge of the clinical area (3, 4, 5, 10, 13 protocol) and another rater stating lack of 
information (3 protocols 1, 8, 9). Imputed values 8/105 = 7.62% of data 
 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .043
a
 -.053 .254 1.312 14 84 .218 
Average Measures .238 -.544 .705 1.312 14 84 .218 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
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Results 4 NO missing data  
5 raters, 15 trials 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .166
a
 -.011 .459 1.997 14 56 .035 
Average Measures .499 -.056 .809 1.997 14 56 .035 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance.  
 
Missing data Flexibility of experimental intervention - Adherence 
Rater Protocol Rationale quote from rater 
2. Did not do 11, 12, 13, 14, 15 
due to time 
 
3. Trialist 1, 8,9 “Not mentioned” 
4. Physiotherapist 3 Not addressed in protocol 
4. Physiotherapist 3, 4, 5, 10, 13 Too far afield of my content to judge. Don’t know enough,  
5. Trialist 3, 4, 5 “no patient removed due to lack of adherence”; “no evidence of selective exclusion”; “deviations 
allowed but recorded”;  
6. Physiotherapist 4, 5, 7, 10 “unclear, no information about usual adherence and encouragement to adhere in the trial”; “I don’t 
think this is an item in this trial”. 
6. Did not do 11, 12, 13, 14, 15 
due to time 
 
8.  Did not do 6, 7, 8, 9, 10, 11, 
12, 13, 14, 15 due to time 
 
11 Did not do 2, 6, 7, 8, 9, 10,  
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Rater Protocol Rationale quote from rater 
11, 12, 13, 14, 15 due to 
time 
12.  1, 3, 6 domains not scored “although mentioned in most study protocols in protocol publications often not enough information 
is given to judge on this” 
12. medical 
practitioner, trialist 
Did not do 11, 12, 13, 14, 15 
due to time, 7 as no 
expertise in area  
 
13. Did not do 6, 7, 8, 9, 10, 11, 
12, 13, 14, 15 due to time 
 
14. Nurse, trial 
methodologist 
1, 5, 9 “Not clear”, “Not reported”, “not clear if have to attend all sessions – some information on 
withdrawals”. 
14. Did not do 11, 12, 13, 14, 15 
due to time 
 
15. medical 
practitioner, trialist 
2, 4, 5 “not discussed”; “unclear to me; intervention is directed at physician who is to follow “local 
protocol”, however, there is no explicit statement that adherence will not be promoted beyond 
usual care”; “inadequately described or not reported – I could not find it”;  
15.  Did not do 7, 8, 9, 10, 11, 12, 
13, 14, 15 due to time 
 
16. Did not do 11, 12, 13, 14, 15 
due to time 
 
17. Did not do 2, 4, 9, 10, 11, 12, 
13, 14, 15 due to time 
 
18. Did not do 1, 2, 3, 4, 11, 12, 
13, 14, 15 due to time. 
 
19. medical 
practitioner, trialist 
3, 4, 5 “not described”; “N/A one time surgery”; N/A one time infusion”. 
19. Did not do 11, 12, 13, 14, 15 
due to time 
 
 
Follow up 
Results 1 
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Sample:  5 trial protocols, 18 raters 
There were 6 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis (4 protocols not completed due to time, 2 as not 
reported in protocol). Imputed values 6/90 = 6.67% of data. 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .240
a
 .064 .753 6.677 4 68 .000 
Average Measures .850 .554 .982 6.677 4 68 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Results 2 
Sample: 12 trial protocols 10 raters 
There were 8 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis (3 protocol not completed due to time, 5 as not 
reported in protocol or uncertain). Imputed values 8/90 = 8.89% of data. 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .252
a
 .094 .574 5.035 9 99 .000 
Average Measures .801 .554 .942 5.035 9 99 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
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b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Result 3 
Sample: 15 trial protocols and 7 raters  
There was one imputed value at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis). Imputed values 1/90 = 1.11% of data 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .174
a
 .031 .435 2.479 14 84 .005 
Average Measures .597 .183 .844 2.479 14 84 .005 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Missing data Follow up 
Rater Protocol Rationale quote from rater 
2. Did not do 11, 12, 13, 14, 15 due to time  
3. 8 “not mentioned” 
6. 9 ? 
6. Did not do 11, 12, 13, 14, 15 due to time  
8.  Did not do 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 due to time  
11. Did not do 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 due to time  
12. medical practitioner, trialist Did not complete this domain in 1, 3   
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Rater Protocol Rationale quote from rater 
12. medical practitioner, trialist Did not do 11, 12, 13, 14, 15 due to time. 7 as no expertise in area  
13. Did not do 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 due to time  
14 4 “Not reported” 
14 Did not do 11, 12, 13, 14, 15 due to time  
15.  Did not do 7, 8, 9, 10, 11, 12, 13, 14, 15 due to time  
16 Did not do 11, 12, 13, 14, 15 due to time  
17. Did not do 2, 4, 9, 10, 11, 12, 13, 14, 15 due to time  
18. Did not do 1, 2, 3, 4, 11, 12, 13, 14, 15 due to time.  
19. Did not do 11, 12, 13, 14, 15 due to time  
 
Outcome 
Results 1 
Sample:  5 trial protocols, 18 raters 
There were 3 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis (3 protocols not completed due to time). Imputed 
values 3/90 = 3.33% of data. 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .231
a
 .060 .745 6.404 4 68 .000 
Average Measures .844 .535 .981 6.404 4 68 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
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Results 2 
Sample: 12 trial protocols 10 raters 
There was 1 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis (1 protocols not completed due to time). Imputed 
values 1/90 = 1.11% of data. 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .139
a
 .025 .429 2.938 9 99 .004 
Average Measures .660 .236 .900 2.938 9 99 .004 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
 
 
 
 
 
 
Result 3 
Sample: 15 trial protocols and 7 raters  
Complete set for ICC analysis, no imputed values. 
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Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .101
a
 -.017 .340 1.788 14 84 .054 
Average Measures .441 -.134 .783 1.788 14 84 .054 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Notes for discussion 
Odd results 2 and 5 scores for protocol 12; “2” by rater 7 “very tight outcome seriologically confirmed” and “2” for rater 4 for protocol 12 “daily diary far 
removed from usual care” 
Missing data Outcome 
Rater Protocol Rationale quote from rater 
2. Did not do 11, 12, 13, 14, 15 
due to time 
 
6. Did not do 11, 12, 13, 14, 15 
due to time 
 
8.  Did not do 6, 7, 8, 9, 10, 11, 12, 
13, 14, 15 due to time 
 
11 Did not do 2, 6, 7, 8, 9, 10, 11, 
12, 13, 14, 15 due to time 
 
12. medical practitioner, trialist Did not do 11, 12, 13, 14, 15 
due to time. 7 as no expertise 
in area 
 
13. Did not do 6, 7, 8, 9, 10, 11, 12, 
13, 14, 15 due to time 
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Rater Protocol Rationale quote from rater 
14 Did not do 11, 12, 13, 14, 15 
due to time 
 
15.  Did not do 7, 8, 9, 10, 11, 12, 
13, 14, 15 due to time 
 
16 Did not do 11, 12, 13, 14, 15 
due to time 
 
17. Did not do 2, 4, 9, 10, 11, 12, 
13, 14, 15 due to time 
 
18. Did not do 1, 2, 3, 4, 11, 12, 13, 
14, 15 due to time. 
 
19. Did not do 11, 12, 13, 14, 15 
due to time 
 
 
Analysis 
 
Results 1 
Sample:  5 trial protocols, 18 raters 
There were 5 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis (3 protocols not completed due to time + 2 due to 
lack of information). Imputed values 5/90 = 5.55% of data. 
 
 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
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Single Measures .214
a
 .052 .729 5.905 4 68 .000 
Average Measures .831 .495 .980 5.905 4 68 .000 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Results 2 
Sample: 12 trial protocols 10 raters 
There were 3 imputed values at 3 = equally pragmatic/explanatory. Thus complete set for ICC analysis (1 protocols not completed due to time and 3 values 
not in protocol). Imputed values 3/90 = 3.33% of data. 
 
Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .182
a
 .050 .489 3.667 9 99 .001 
Average Measures .727 .388 .920 3.667 9 99 .001 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Result 3 
Sample: 15 trial protocols and 7 raters  
Complete set for ICC analysis, no imputed values. 
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Intraclass Correlation Coefficient 
95% Confidence Interval F Test with True Value 0  Intraclass 
Correlation
b
 Lower Bound Upper Bound Value df1 df2 Sig 
Single Measures .221
a
 .064 .489 2.990 14 84 .001 
Average Measures .666 .322 .870 2.990 14 84 .001 
Two-way random effects model where both people effects and measures effects are random. 
a. The estimator is the same, whether the interaction effect is present or not. 
b. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded from the 
denominator variance. 
 
Missing data Analysis 
Rater Protocol Rationale quote from rater 
2. Did not do 11, 12, 13, 14, 15 
due to time 
 
4 8 “No mention of ITT, per 
protocol discussed at length” 
6 1, 8 , 10 “Not clear, the sentence “data 
cleaning….” Suggests it to be 
more explanatory”;  
11 Did not do 2, 6, 7, 8, 9, 10, 11, 
12, 13, 14, 15 due to time 
 
12 Did not complete this domain 
in 3, 5 
“not clear if ITT or PP primary 
analyses”. 
12 Did not do 11, 12, 13, 14, 15 
due to time. 7 as no expertise 
in area 
 
13 4 - (none given) 
13. Did not do 6, 7, 8, 9, 10, 11, 12,  
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Rater Protocol Rationale quote from rater 
13, 14, 15 due to time 
14 Did not do 11, 12, 13, 14, 15 
due to time 
 
15.  Did not do 7, 8, 9, 10, 11, 12, 
13, 14, 15 due to time 
 
16 2 “Analysis is not ITT as excludes 
all participants who do not take 
first dose.” 
16 Did not do 11, 12, 13, 14, 15 
due to time 
 
17 Did not do 2, 4, 9, 10, 11, 12, 
13, 14, 15 due to time 
 
18. Did not do 1, 2, 3, 4, 11, 12, 13, 
14, 15 due to time. 
 
19. Did not do 11, 12, 13, 14, 15 
due to time 
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Chapter 8 Internal and external validity 
 
Table 8.1 with details of variables in proposed matched studies 
Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
Bots 
2005[23] 
 
Rosuvastatin 
10mg 
Achieving 
European 
LDL-C goal 
(<3.0 
mmol/l) at 
week 12 
152 
primary 
care 
centres in 
Netherland
s 
1215 4 (rather 
pragmatic) 
61 (9.7) for 
intervention; 
62 (9.2), 62 
(9.3), and 60 
(9.3) for 
comparator  
CHD risk at 
baseline. Very 
high (>40%): 
34% 
intervention; 
34, 38, 27% 
for 
comparators 
12 weeks RD 17.16% 
More patients 
achieved 1998 
and 2003 
European goals 
w. Rosuvastatin 
(p < 0.001); 
75.4% 
Rosusvastatin 
10mg achieved 
vs Arovastatin 
10mg 58.7%  
Unclear 
 
 
 
 
 
 
Davidson 
[24] 
 
Rosuvastatin 
10mg 
% change in 
LDL 
cholesterol 
from 
baseline - 
week 12 
(European 
52 in North 
America 
519 2  
(rather 
explanatory) 
56.4-57.9 ± 
12.7 
Fasting low 
density 
lipoprotein 
(LDL) 
cholesterol ≥ 
4.8 mmol/L 
(0.5) all 
12 weeks RD 11.15% 
Secondary 
outcome to 
match outcome 
in Bots trial:84% 
Rosuvastatin 
Unclear 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
goal at week 
12 was 
2ndry goal 
groups 10mg achieved 
vs 73% Arovast-
atin 10mg 
 
Brady 
[15] 
 
B-blocker – 
metoprolol 
Fatal and 
non-fatal 
cardiovascul
ar events 
(namely MI, 
unstable 
angina, 
ventricular 
tachycardia, 
or stroke) 
within 30 
days of 
operation 
4 103 3 (= 
explanatory/
pragmatic) 
Placebo74 
median (66-
76); 
Metoprolol 
73 (61-79) 
Requiring 
vascular 
surgery 
32 
months: 
From July 
2001 and 
March 
2004 
RD = -0.34% NS 
 
 
- 
Yang[25] 
 
B-blocker 
metoprolol  
Fatal and 
non-fatal 
cardiovascul
ar events 
(namely MI, 
unstable 
3 496 2(rather 
explanatory) 
Placebo 
65.9±10;   
 
Metropol 
Requiring 
vascular 
surgery 
3 years 36 
months 
RD – 1.84% 
 
RRD 15.3% 
(95%CI -38.3% 
- 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
angina, 
ventricular 
tachycardia, 
or stroke) 
within 30 
days of 
operation 
66.4±10 to 48.2%) 
Covas 
[16] 
 
25ml of Extra 
virgin olive oil 
Changes in 
biomarkers 
of oxidative 
damage to 
lipids 
6 200 2 (rather 
explanatory) 
20-60 Normal 
healthy, non-
smokers 
checked with 
clinical record, 
physical exam, 
blood 
pressure 
normal, 
normal blood 
test results 
10 mnths: 
September 
2002 
through 
June 2003 
Oxidative stress 
markers 
decreased 
linearly with 
increasing 
phenolic 
content. Mean 
changes for 
oxidized low-
density 
lipoprotein level 
were P = 0.014 
– 3.21 U/L (-5.1 
to -0.8 U/L) for 
the high-
polyphenol olive 
oil. 
Values are 
means ± SD , 
n=12 for each 
group 
 
 
51 
 
Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
Bogani 
[26] 
 
50ml Extra 
virgin olive oil  
together with 
150g of 
potatoes 
Composite – 
blood anti-
inflammator
y markers 
(TXB2 and 
LTB4) and 
oxidative 
stress 
markers  
1 12 1 (very 
explanatory) 
25 ± 3 normolipede
mic healthy 
subjects 
Unclear 
2005 – 2 
weeks run 
in period 
plus 1 day 
At 2 hours (P = 
0.006) increase 
in antioxidant 
capacity after 
consumption of 
EVOO, 
difference in 
serum 
antioxidant 
capacity 
between EVOO 
and Corn Oil 
group (P=0.013) 
Unclear 
Dorman 
[27] 
 
administration 
of nicardipine 
or 
nitroprusside 
Rapidity and 
variability of 
blood 
pressure 
control 
1 60 3 (= 
explanatory/
pragmatic) to 
4 (rather 
pragmatic) 
70±10 
nicardopine 
(NIC)/ 
67.3±10 
Nitroprussid
e (SNP) 
preoperative 
BP NIC 155±24 
SNP 159±21/ 
NIC 75±10 SNP 
80±10 
diastolic 
 
 
10-month 
1995-1996 
Nicardipine: 
Therapeutic 
response 
approx. 15min; 
Nitropruss: 
Therapeutic 
response 
approx. 60mins 
(more variation) 
p < 0.01 
Unclear 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
Halpern 
[28] 
 
administration 
of iv 
nicardipine or 
sodium 
nitroprusside 
BP/Heart 
Rate; 
Therapeutic 
response 
rate 
6 139 2 (rather 
explanatory) 
55-75 systolic NIC 
151±2 & SNP 
151±3; NIC 
81±2  & SNP 
78±2 diastolic 
14 months 
June 1988 
to July 
1989 
Cardiac surgery 
[n=51] 
Nicardipine: 
Therapeutic 
response 
14.0±1.0[SEM] 
mins 
[n=51] 
Nitropruss: 
Therapeutic 
response 
30.4±3.5 min 
(p=0.0029) 
Mean ± SEM 
Goy [29] Stents during 
angioplasty – 
Siromulus  
Reduction in 
major 
cardiac 
events 
(MACE) 
1 
(Switzerlan
d)  
202 4 (rather 
pragmatic) 
63-65 ± 10 Requirement 
Percutaneous 
Coronary 
Intervention 
(PCI) 
6 months MACE Events 
Siromulus 
(6/102); Events 
Paclitaxel 
(4/100) RD 1.88. 
Measured at 6 
months 
  
 
Unclear 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
Morice 
[30] 
Stents during 
angioplasty – 
Siromulus 
Reduction in 
major 
cardiac 
events 
(MACE) 
19 238 1 (very 
explanatory) 
60.7±10.4 Requirement 
Percutaneous 
Coronary 
Intervention 
(PCI) 
12 months MACE Events 
Siromulus 
(7/120); Events 
normal (34/118) 
RD -22.98%. 
Measured at 
least 6 months – 
average 7 
months±2.  
Unclear 
Kaiser 
[31] 
Stents during 
angioplasty  
Reduction in 
major 
cardiac 
events 
(MACE) 
1 826 4 (rather 
pragmatic) 
64±10 Required PCI 
and stenting 
12.5 
months: 
May 5, 
2003 to 
May 31, 
2004 
RD -3.56 % 
(p=0.02) 
Unclear 
OR 0.56 (95% 
CI 0.35 – 0.91) 
Grube 
[32] 
Stents during 
angioplasty 
TAXUS 
(Paclitaxel 
release)  
Reduction in 
major 
cardiac 
events 
(MACE) 
3 61 2 (rather 
explanatory) 
TAXUS: 
66±6.8  NIR: 
63.8±7.8 
Single de-novo 
or target 
lesions 
6 months: 
Between 
October 
2000 and 
March 
2001 
RD -6.67 % (NS) Unclear 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
Kedhi 
[33] 
Paclitaxel 
releasing stents 
during 
angioplasty 
(comparison 
everolimus) 
2ndry 
outcome 
used: MACE 
12 months 
1 1800 4/5 
(very/rather 
pragmatic) 
63.6 (55.7-
72.9) 
Paclitaxel: 
62.9 (55.4-
71.1) 
Everolimus 
Coronary 
artery disease 
18 
months: 
February 
2007 to 
September 
2008 
Paclitaxel 8% vs 
Everolimus-
eluting stents 
5%: RD 3.29% p 
= 0.005 
 
Unclear 
 
Grube 
[32] 
Paclitaxel 
releasing stent 
during 
angioplasty 
(comparison 
bare metal 
stent)  
 
Reduction in 
major 
cardiac  
events 
(MACE) 
3 61 2 (rather 
explanatory) 
TAXUS: 
66±6.8  
BMS: 
63.8±7.8 
Single de-novo 
or target 
lesions 
12 
months: 
Between 
October 
2000 and 
March 
2001 
RD -6.67 % Unclear 
Koren 
[34] 
Arorvastatin 
maximum dose 
80mg/day 
titrated to LDL-
C goals of < 80 
mg/dl (2.1 
mmol/l) 
 % reduction 
in LDL-C 
levels 
16 2442 Rather 
pragmatic 
Arvorvastati
n 61.6 (9.0); 
Usual care 
61.3 (8.6) 
Known CHD 
defined as a 
history of 
acute 
myocardial 
infarction (> 3 
months 
3 years – 
July 1995- 
June 1998 
Mean change 
34.3% (p 
<0.0001) RD 
0.92% 
LDL-C Levels  
mean ± SD 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
before 
screening),  
PCTA (> 6 
mths before 
screening), 
coronary 
artery bypass 
graft surgery 
(> 3 mths 
before 
screening), 
unstable 
angina (> 3 
mths before 
screening) 
Jones 
[35] 
Arorvastatin 
10, 20, 40, 80 
mg compared 
with 
simvastatin, 
pravastatin, 
lovastatin and 
fluvastatin 
Mean 
change in 
plasma LDL 
cholesterol 
from 
baseline to 
the end of 
treatment (8 
wks). 
34 sites 534 Rather 
explanatory 
55 17% patients 
had CAD 
8 weeks;  Mean change 
38% (p = 
0.0001) 
RD 12.5% 
± SD 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
Piller [36]  Doxazosin 
compared with 
Lisinopril (10-
40mg/d), 
amlodipine 
(2.5-10mg.d) 
CVD 
mortality 
(death due 
to CHD, 
Stroke, HF, 
or other 
CVD).  
623  32804 Rather 
pragmatic 
66.7 HF (7.6) High risk 
hypertensive 
patients, BP > 
140mm Hg 
and/or 
diastolic  BP of 
90mm Hg or 
higher, and/or 
taking  
antihypertensi
ve medication 
(< 3 drugs) 
with a BP of 
160/100 mm 
Hg and had at 
least one 
additional 
CHD risk 
factor 
February 
23
rd
 1994 
to 31
st
 
2002 -
Active 
follow up.  
Then 
databases 
until Dec 
2006 – 4 
years.  
RD -0.39% 
(doxazosin vs 
Lisinopril and 
amlodipine) 
HR 3.81 (3.29-
4.41), p<0.001 
Grimm 
[37] 
Doxazosin (2-
16mg) 
compared with 
hydroclorothiaz
ide 
Composite: 
blood 
pressure, 
biochemistri
es, 
lipids/lipopr
2 
Minneapol
is and 
Chicago  
107 Rather 
explanatory 
56.3 Baseline 
severity: DBP 
≥ 96 mm Hg 
and < 110 mm 
Hg 
8 weeks? doxazosin 
lowered  
(-19 and -16 
mm Hg); HCTZ (-
22 and 15 mm 
SE 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
(chorthalidone 
5-50mg) 
oteins, 
quality of 
life, 
ambulatory 
electrocardi
ograms, 
echocardiog
rams, 
adverse 
experiences, 
and drug 
adherence 
Hg) 
Schiariti 
[38] 
high dose 
tirofiban 
25µg/kg bolus 
followed by 
0.15 µg/kg per 
min for 18 hour 
infusion; 
comparator = 
double bolus 
eptifibatide 
180µg/kg 
bolus, followed 
by 2µg/kg per 
min 18-h 
Incidence of 
composite 
ischaemic 
events 
within one 
year 
1 675 Pragmatic 62±11 Coronary 
Ischaemia that 
requires 
Percutaneous 
Coronary 
Intervention 
24 
months: 
February 
2005 and 
March 
2007 
Effect size 
within 1 year  
9.1% tirofiban 
group and 
12.2% in 
eptifibatide 
group (P=0.22) 
Unclear 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
infusion and 
10min after 2
nd
 
180 µg/kg 
bolus, 
Topol 
[39] 
Tirofiban bolus 
10 µg per 
kilogram of 
body weight 
followed by 
and infusion of 
0.15 µg per 
kilogram per 
min for 18-24 
hours; 
comparator = 
abciximab 
bolus 0.25mg 
per kg, 
followed by 
infusion0.125 
µg per kg per 
min (12 hours). 
MACE within 
30 days of 
index 
procedure - 
PCI 
149 2647 Explanatory 62±11 Coronary 
Ischaemia  
- Requirement 
PCI 
Nearly 8 
months: 
December 
30th 1999 
to August 
25th 2000 
Effect size 30 
days – 7.6% 
tirofiban group 
and 6.0% in 
abciximab 
group; Hazard 
ratio 1.26; 95% 
CI 
(1.01 to 1.57); 
P=0.038 
Smits [40] Paclitaxel stent 
(comparison 
Everolimus 
Composite 
of all death, 
nonfatal MI, 
1  1800 Pragmatic PES 63.6;  
EES 62.9  
High number 
of patients 
with acute 
2 years; 
February 
2007 to 
Paclitaxel stent 
vsEverolimus 
stent:  RD 2.95 
Unclear 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
stent) 
 
and TVR at 
12 months. 
coronary 
syndrome 
(59% PES vs 
60% EES), 
most lesions 
complex 
September 
2008 
(p = 0.02) 
Iry outcome RR 
0.66; 95% CI 
 
(0.50-0.86) 
 
Grube 
[32] 
Paclitaxel 
releasing stent 
during 
angioplasty 
(comparison 
bare metal 
stent)  
 
Reduction in 
major 
cardiac  
events 
(MACE) 
3 61 2 (rather 
explanatory) 
TAXUS: 
66±6.8  
BMS: 
63.8±7.8 
Single de-novo 
or target 
lesions 
12 
months: 
Between 
October 
2000 and 
March 
2001 
RD -6.67 % Unclear 
Suh[14] Drug - 
Cilostazol 
(loading dose 
200mg, then 
100mg BD for 6 
months) 
Composite 
of major 
adverse 
cardiovascul
ar events, 
cardiac 
death, non-
fatal MI, 
clinically 
5 960 Explanatory 64 Coronary 
artery disease  
Baseline 
severity: 
Intracoronary 
drug-eluting 
stents (DES) 
30 
months: 
September 
2006 to 
June 2009 
RD -0.64% 
p=0.73 
Unclear 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
driven 
target lesion 
revasculariz
ation (TLR) 
and 
ischemic 
stroke at 6 
months 
Douglas 
[41] 
Intervention = 
clopidogrel 
75mg so TAT 
(asprin, 
clopidogrel and 
ccilostazol 
100mg BID); 
comparator = 
DAT (dual 
antiplatelet 
therapy) aspirin 
and  
clopidogrel   
 
minimal 
luminal 
diameter of 
the first 
lesion 
19 705 Pragmatic 60 (10) Narrowing in 
native  
arteries after  
successful 
coronary stent 
implantation 
18 
months: 
November 
2001 and 
April 2003 
RD -0.05% 
p=0.89 
 
± SD 
Van 
Birgelen 
Drug - 
Zotarolumus-
Acute 
coronary 
1 1391 4 (rather 64.2 ± 10 coronary 
syndromes  
15 
months: 
RD 0.11% p=94 Unclear 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
[42] eluting 
Resolute stents 
syndromes 
at 12 
months 
pragmatic) undergoing 
PCI and stent 
insertion 
June 2008 
- August 
2010 
Serruys 
[43] 
Intervention = 
Zotarolimus-
eluting stents; 
comparator = 
Everolimus-
eluting stent 
Target-
lesion failure 
- composite 
of death 
from cardiac 
causes, any 
myocardial 
infarction 
(not clearly 
attributable 
to a non-
target 
vessel) or 
clinically 
indicated 
target-lesion 
revascularis
ation at 12 
months 
22 2292 5 (very 
pragmatic) 
64.2 ± 10.8 stable 
coronary 
disease or 
acute 
coronary 
syndromes  
Baseline 
severity: 
Requiring 
stents 
6 months: 
April 30 
2008 to 
October 
2008 
RD -0.57% 
p=0.66 
Unclear 
 
Zhu [44] Intervention = 
10mg 
Achieving 
European 
152 1215 4 (Rather 60-62 (9.3- Fasting LDL-
Cholesterol of 
unclear RD 17.16% (p < Unclear 
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Study Intervention Primary 
outcome 
No. of 
centres 
Sample 
size 
(number 
rand’d) 
Degree of 
pragmatism 
Participant 
Age –Mean 
(SD) 
Participant 
baseline 
severity 
Duration 
of trial 
Effect sizes 
Risk Difference 
(RD) if possible. 
Measures of 
variance for 
primary 
outcome  
rosuvastatin; 
comparator = 
10mg 
arorvastatin 
LDL-C goal 
(<3.0 
mmol/l) at 
week 12 
pragmatic) 9.7) >3.5 mmol/l if 
untreated or 
fasting LDL-C 
of >3.1 mmol/l 
if currently 
being treated 
with start 
dose of other 
lipid lowering 
therapy. 
0.001) 
Olsson 
[45] 
Intervention = 
10mg 
rosuvastatin; 
comparator = 
10mg 
arorvastatin 
 
LDL-C 
reductions 
6 412 1 (very 
explanatory) 
56-58 ± 10 Hypercholeste
rolemia  
Baseline 
severity: LDL-C 
160 and 
<250mg/dL 
52 week: 
1999 to 
2000 
Reduction in 
LDL-C 46% 5mg 
and 50% 10mg 
vs 39%, both P < 
0.001 
Unclear 
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Table 8.2 Comparison of 14 matched pairs of pragmatic and explanatory trials of cardiovascular trials. 
Duplicate entry ST six trials  
The latter two were not always possible, which meant a comparison of estimates of treatment effect was not possible.  A Cochrane Risk of Bias assessment 
[113] was possible, which is shown here.   
Each pair of matched trials are grouped by row colour: white or shaded.  The degree to which a trial was pragmatic or explanatory varied considerably; some 
pragmatic/explanatory trials were much more pragmatic/explanatory than others.   
Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Bots [177] 
 
Intervention = 
Rosuvastatin 10mg; 
comparator = 
arorvastatin 10mg, 
simvastatin 20mg, 
pravastatin 40mg, 
Unclear 
Unclear 
Unclear 
Unclear 
 
Low risk (open label – 
intention of researchers 
to test usual care in 
primary care setting 
Unclear 
Low risk 
Low risk 
Low risk 
Low risk  
Unclear - Analysis not 
per-protocol intention 
to treat, but changed 
during study to add 
additional analysis. 
Low risk 
 
 
 
 
 
Unclear 
Unclear 
 
Pragmatic  
Pragmatic ST 
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Davidson [178] 
 
Intervention =  
Rosuvastatin 5mg or 
10mg ; comparator =  
arorvastatin 10mg,  
 
Unclear 
Unclear  
Unclear 
Unclear  
Unclear 
Low risk 
Low Risk 
High risk 
 
Low risk 
Low risk 
Unclear (violations 
leading to exclusion, 
deviations leading to 
exclusion, 
withdrawals) all 
detailed and adverse 
events 
Low risk 
 
 
 
Unclear 
High 
risk 
Explanatory  
Explanatory ST 
 
Brady [163] 
 
Intervention = oral 
metoprolol 50mg 
twice daily, 
supplemented by IV 
doses when 
necessary; 
comparator = 
placebo 
 
Low risk: Randomisation 
at 
TheSealedEnvelope.com 
Web site p603 
Low Risk: 
Treatment 
allocated in a 1:1 
ration by using 
random 
permuted blocks 
of size 2, 4, 6 
within 4 
stratification 
factors p603 
Low risk: Patients, 
doctors, medication 
identical appearance 
numbers for ID 
purposes for patient 
and drug. No evidence 
unblinding occurred. 
Unclear about outcome 
assessment but says 
DMEEC blinded 
comparison p603 
 
Low risk Low risk Low risk Low risk 
Pragmatic  
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Yang [166] 
 
Intervention = 
metoprolol 100mg; 
comparator = 
placebo 
Low risk Unclear Low risk 
 
 
 
 
 
 
 
 
 
Low risk Low risk Low risk 
 
Low risk Explanatory 
 
Covas [169] 
 
Intervention = olive 
oil high phenolic 
content (virgin olive 
oil) 2.7mg/kg; 
comparator =  olive 
oil moderate and low 
phenolic content  
Low risk (taken from a 
latin square for each 
centre by blocks of 42 
participants (14 people in 
each sequence) using 
specific software was 
that was developed at 
the Institute Medical 
Research, Barcelona, 
Spaion 
 
p335 
Low risk – faxed 
to participating 
centres upon 
request for each 
individual 
Low risk code number 
for treatment containers 
concealed from 
participants and 
investigators only 
disclosed after 
analyses.  
Low risk Low risk Unclear: Couldn’t 
assess potential 
interactions between 
other dietary 
constituents, self 
reporting of diet, full 
consumption of oil 
treatment, short 
treatment period 
Low risk Pragmatic 
 
Bogani[179] 
 
 
Intervention = extra 
virgin olive oil; 
comparator = oilive 
and corn oil 
Low risk, latin square 
design  
Unclear High risk, un-blinded for 
men, investigators and 
outcome assessors 
Low risk Low risk High risk – self 
selected group, all 
men. 
 
Unclear Explanatory 
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Dorman [180] 
 
 
Intervention = 
nicardipine; 
comparator = 
nitroprusside 
Unclear - Randomisation 
by investigation 
pharmacy 17p 
Unclear Low risk – both covered 
with foil so appeared 
identical to nurse who 
was also measuring 
outcomes p17 
Low risk Low risk Unclear 
 
Unclear Pragmatic 
 
Halpern [181] 
 
 
Intervention = 
nicardipine; 
comparator = 
nitroprusside 
Unclear 
Randomisation was by 
pre-assigned entry 
number without regard to 
the type of surgical 
procedure performed 
 
P1638 
Unclear High risk A coded open 
label solution was 
prepared. Sodium 
nitroprusside solution 
was wrapped in an 
opaque material to 
prevent denaturation by 
light 
High risk - 
Not ITT, only 
adverse 
effects for all 
139 patients, 
3 excluded 
from analysis 
regarding 
results of 
maintenance 
therapy and 
22 excluded 
from analysis 
at 
therapeutic 
response 
Low risk Unclear 
 
Unclear  
Explanatory  
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Goy [182] 
 
 
Intervention = 
paclitaxel-eluting 
stents; comparator = 
sirolimus-eluting 
stents 
Unclear UNCLEAR Unclear 
UNCLEAR 
Unclear 
UNCLEAR 
Low  risk 
Low risk 
Low 
Low risk 
Unclear 
Low risk 
Unclear 
 
UNCLEAR 
Pragmatic 
 
Pragmatic ST 
 
Morice[183] 
 
 
Intervention = 
paclitaxel-eluting 
stents; comparator = 
standard uncoated 
stents 
P1174 Low risk - codes 
for random assignments 
to the treatment groups 
were generated by 
computer in blocks of 
four  
Low risk 
P1174 Low risk -
distributed in 
sealed envelopes 
to each 
participating 
center. 
Low risk 
 
 
 
 
 
P1174 Low risk. Double 
blind  - The sirolimus-
eluting stents were 
indistinguishable, 
except under a 
microscope, from the 
uncoated stents. 
Outcome assessment 
central adjudication. 
Low risk 
Low risk 
Low risk 
 
 
 
 
 
 
 
Low risk 
Low risk 
 
 
 
 
 
 
 
 
Low risk 
Low risk 
 
 
 
 
 
 
Low risk 
Low risk 
 
 
 
 
 
 
Explanatory 
 
explanatory ST 
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Kaiser [184] 
 
 
Intervention = 
Sirolimus-coated  
Cypher  or paclitaxel-
coated Taxus drug-
eluting stents; 
comparator = cobalt 
chromium-bare metal 
Vision stents 
Unclear how  patients 
randomised- The 
operator in charge 
enrolled all patients 
being treated with PCI 
and stenting, and 
patients were 
randomised at midnight 
at the beginning of each 
day’s clinic to one of 
the three stent types by 
use of sealed envelopes. 
Low risk 
Low – sealed 
envelopes 
Low risk 
Low risk – patients 
knew and so did 
surgeons. Unlikely to 
have effect on outcome.  
All outcome events 
were 
adjudicated by an 
independent Critical 
Events 
Committee blind to the 
stent type used. 
Low risk 
Low risk 
Low risk 
Low risk 
Low risk 
Unclear 
Low risk 
 
Low risk 
Low risk 
Pragmatic  
 
 
Pragmatic ST 
 
Grube [185] 
 
Intervention = 
everolimus-eluting 
stents; comparator = 
bare metal stents 
Unclear 
Unclear 
 
Unclear 
Unclear  
 
Strictly double blinded 
analysis. To maintain 
blinding packaging, 
stents were 
indistinguishable by 
physical and 
radiographical 
appearance. Cath labs 
and clinical events 
committee blinded to 
treatment groups 
Low risk 
 
Low risk 
Low risk 
 
 
 
Low risk 
Low risk 
 
 
Low risk 
High risk 
 
 
Low risk 
High 
risk 
 
 Explanatory  
Explanatory ST 
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Kedhi [186] 
 
Intervention = 
everolimus-eluting 
stents; comparator = 
paclitaxel-eluting 
stents 
Low risk - Computer 
generated p201 
Low risk - 
Sealed, opaque 
sequentially 
numbered 
allocation 
envelopes 
AFTER passage 
of guide wire 
Patients didn’t know 
WHICH stent 
Low risk Low risk Unclear 
 
Low risk 
Pragmatic  
Grube [185] 
 
 
Intervention = 
everolimus-eluting 
stents; comparator = 
bare metal stents 
Unclear Unclear Strictly double blinded 
analysis. To maintain 
blinding packaging, 
stents were 
indistinguishable by 
physical and 
radiographical 
appearance. Cath labs 
and clinical events 
committee blinded to 
treatment groups 
Low risk Low risk Low risk 
 
Low risk 
Explanatory  
Koren[187] 
 
 
Intervention = 
arorvastatin max 
dose 80mg/day; 
comparator = usual 
care – any treatment 
deemed appropriate 
by physician 
Unclear – randomisation 
by central laboratory 
Unclear Low Low - An 
independent 
outcomes 
committee of 
five 
cardiologists 
reviewed 
and 
adjudicated 
all study 
outcomes. 
Low risk Unclear - Privacy 
issues contributed to 
difficulties with follow 
up information data 
that would not have 
occurred had the 
study been performed 
entirely in a 
Research setting. 
Recruitment was 
through databases so 
no relationship with 
doctors and patients 
pre-existed. 
Unclear 
Pragmatic  
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Jones [188] 
 
Intervention = 
arorvastatin 10mg, 
20mg, 40mg and 
80mg; comparator = 
simvastatin 10, 20, 
40mg, provatatin 10, 
20, 40mg, lovastatin 
20, 40, and 80mg 
and fluvastatin 20, 
40mg 
Unclear Unclear High Risk Unclear Unclear Unclear 
 
Unclear 
Explanatory  
Piller [189] 
 
Intervention = 
calcium channel 
blocker -amlodipine 
(2.5-10mg/d) and 
angiotensin 
converting enzyme 
inhibitor Lisinopril 
(10-40mg/d); 
comparator = 
chlorothiadone (12.5-
25mg/d) 
Unclear, looked at 
protocol and DSMB will 
monitor recruitment to 
decide  
Central allocation 
- Called up 
Clinical Trials 
Centre to get 
randomisation 
p347 
 Blinding but choice of 
primary outcome 
(mortality) should 
prevent bias p 345 [190] 
Davis et al) 
Problems 
with 
Canadian 
centres no 
access to 
database to 
assess 
outcomes. 
Does not 
appear to 
be 
selective 
Final stopping rule, 
used in one of the 
arms. 
 
Low risk 
Pragmatic  
Grimm [191] 
 
 
Intervention = 
diuretic 
hydrochlorothiazide 
(HCTZ) 
(Chlorothiadone) 25-
50mg; comparator = 
α1 antagonist - 
doxazocin (2-16mg)  
Low risk - 
Randomization was 
carried out by a 
computer-generated, 
coded list, which was 
stratified by clinic site. 
 
Unclear Low risk. Participants 
blinded and doctors 
added drug to study 
drug in blinded fashion, 
measurements done by 
individuals who appear 
to be blinded as well. 
Low risk Low risk Unclear 
 
Low risk Explanatory 
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Schiariti [192] 
 
Intervention = high 
dose tirofiban 
25µg/kg bolus 
followed by 0.15 
µg/kg per min for 18 
hour infusion; 
comparator = double 
bolus eptifibatide 
180µg/kg bolus, 
followed by 2µg/kg 
per min 18-h infusion 
and 10min after 2nd 
180 µg/kg bolus, 
Low risk - Block 
randomisation scheme, 
75 blocks of five and 75 
blocks of four patients. 
Unclear Low risk - Open label, 
an external reviewer 
unaware of treatment 
assignment coded all 
events.  
High risk – 
as treated 
analysis 
rather than 
ITT 
Low risk Unclear Unclear Pragmatic 
 
Topol [193] 
 
Intervention = 
Tirofiban bolus 10 µg 
per kilogram of body 
weight followed by 
and infusion of 0.15 
µg per kilogram per 
min for 18-24 hours; 
comparator = 
abciximab bolus 
0.25mg per kg, 
followed by 
infusion0.125 µg per 
kg per min (12 
hours). 
Low risk – use of a 
central interactive 
system.Patients 
randomised on the basis 
of prior angiographic 
findings before 
intervention was begun.  
Unclear Low risk - Double blind 
and remained blinded 
until primary end points 
finalised and entered. 
Outcome assessment 
by  
Low risk - 
ITT 
Low risk Low risk Low risk Explanatory 
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Smits [194] 
 
Intervention  
everolimus-eluting 
stents; comparator = 
paclitaxel-eluting 
stents 
Low risk - computer-
generated random 
numbers. 
Low risk - using 
sealed, opaque, 
sequentially 
numbered 
allocation 
envelopes after 
passage of the 
guide wire. 
Low risk – could not 
blind surgeons, blinded 
outcome assessment. 
Patients did not know 
either. 
Low risk Low risk Unclear Low risk 
Pragmatic  
Grube [185] 
 
 
Intervention = 
everolimus-eluting 
stents; comparator = 
bare metal stents 
Unclear Unclear Strictly double blinded 
analysis. To maintain 
blinding packaging, 
stents were 
indistinguishable by 
physical and 
radiographical 
appearance. Cath labs 
and clinical events 
committee blinded to 
treatment groups 
Low risk Low risk Low risk 
 
Low risk 
Explanatory  
Suh [168] 
 
Intervention = 
cilostazol 200mg and 
100mg twice daily so 
TAT (asprin 300mg, 
clopidogrel 300-
600mg and 
ccilostazol); 
comparator = DAT 
(dual antiplatelet 
therapy) aspirin and  
clopidogrel  
Unclear Unclear Unclear. Open label 
trial. Blinded evaluation. 
Possible bias related to 
treatment Target legion 
revascularisation (TLR) 
High risk. 
Intention to 
treat but was 
actually “as-
treated” as 
did not 
analyse all 
randomised. 
Low risk Unclear 
 
Unclear 
Pragmatic  
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Douglas[195] 
 
Intervention = 
clopidogrel 75mg so 
TAT (asprin, 
clopidogrel and 
ccilostazol 100mg 
BID); comparator = 
DAT (dual 
antiplatelet therapy) 
aspirin and  
clopidogrel   
 
Unclear – p2826. The 
coordinating 
center developed a 
randomization scheme. 
 
Low risk 
matching 
unmarked bottles 
of 50 mg 
cilostazol and 
placebo were 
prepared 
with a patient 
allocation 
number. Each 
site received a 
list of 
sequential 
allocation 
numbers. 
Unclear, patients and 
doctors blinded so 
double blinded but no 
mention if blinding 
successful - Outcome 
assessment 
independent  
High risk -
Outcome 
data for all 
patients who 
had 
angiography 
at 6 months 
but that was 
only 74.6% 
of patients 
so “as- 
treated" 
analysis 
performed 
Low risk  Unclear 
 
Unclear 
Explanatory  
von Birgelen [196] 
 
Intervention = 
Zotarolimus-eluting 
stents; comparator = 
Everolimus-eluting 
stent 
Low risk – p1351 
computer-generated 
random numbers (block 
stratified randomization 
version 5.0 by S. 
Piantadosi) 
Low risk – p1351 
sealed opaque 
sequentially 
numbered 
allocation 
envelopes after 
passage of the 
guidewire or pre-
dilation if 
necessary 
Low risk p1352 Patients 
no knowledge of the 
stent type allocated to 
(single blinded design). 
Follow up and outcome 
assessment blinded. 
Central adjudication. 
Low risk Unclear 
did not 
pre-specify 
all 
subgroup 
analysis.  
Low risk 
 
Low risk 
Pragmatic  
Serruys [197] 
 
Intervention = 
Zotarolimus-eluting 
stents; comparator = 
Everolimus-eluting 
stent 
Unclear Unclear Low risk. Patients 
blinded, stents so 
unlikely be able to find 
out. Surgeons knew. 
Subgroups unknown to 
outcome adjudicators. 
Low risk Unclear Low risk 
 
Unclear 
Explanatory  
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Trial Random Sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other sources bias Overall 
Risk of 
Bias 
PRECIS wheel 
Zhu[198] 
 
 
Intervention = 10mg 
rosuvastatin; 
comparator = 
10mgarorvastatin 
Unclear Unclear Low risk (open label – 
intention of researchers 
to test usual care in 
primary care setting 
Low risk Low risk Unclear - Analysis not 
per-protocol intention 
to treat, but changed 
during study to add 
additional analysis. 
 
Unclear 
Pragmatic  
Olsson[199] 
Intervention = 10mg 
rosuvastatin; 
comparator = 
10mgarorvastatin 
 
 
 
Unclear Unclear Unclear Low risk Low risk Low risk Unclear Explanatory 
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Table 8.3 Risk of Bias Domain descriptions for all trials included in the Cochrane Review on hypertension 
Duplicate entry ST four trials 
Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
1 ATTMH[23] 
High-dose thiazide 
Unclear  
Unclear  
 
mention randomly 
allocated 
randomisation code 
Unclear 
Unclear  
 
randomisation code 
Low 
Unclear  
 
Patients blinded – 
identical tablets, 
health care providers 
not blind. blind 
outcome 
assessment 
High 
Unclear  
 
Same number lost to 
follow up in active as in 
placebo groups. 
Reasons for stopping 
same. “On treatment” 
as well as ITT but no 
adjusted rates data in 
article. 
Third patients 
prematurely stopped 
treatment randomised 
to but similar in active 
and placebo. More 
withdrawals by doctors 
in placebo. (195 vs 
110). No attempts 
made to correct for 
such bias. 
 
Low 
Unclear  
 
High 
Unclear  
 
Stopped early due to 
data dependent 
process. A lot of 
discussion about 
Australian trial 
results and 
retrospective 
analysis  
 
High 
Unclear  
 
2 Barraclough[19] 
High-dose thiazide  
Low 
Appears to be block 
randomisation 
 Unclear 
No mention of 
allocation 
High risk 
Doctor knew. Not 
clear if patient 
High risk 
Withdrawn if poor 
attendance, 17 
Low  
Low risk 
High 
Groups do not 
appear to be similar 
High 
High risk 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
“allocated at random, 
series balanced for 
age and sex after 
every 10 allocations” 
Unclear 
concealment at all. 
 
Unclear 
blinded. No 
discussion of blinded 
outcome – 
assumption dr took 
BP. 
Low risk 
withdrawn medical 
reasons and 19 left for 
non-medical reasons 
out of total of 58. Not 
balanced between 
control and treatment 
groups. 
High risk 
 
 at baseline when 
mean weight, blood 
urea, source 
compared, no info on 
statistical 
significance. One 
patient each group 
had ECG 
abnormalities and 
none had evidence 
of probable coronary 
disease. More 
abnormalities in 
control group. 
Unclear 
 
 
3 Carter [48] 
High-dose thiazide 
Unclear Unclear High risk 
 
No mention of 
blinding for patients, 
doctors or outcome 
assessment  
Low risk 
 
"Of the 99 patients in 
the trial, 2 have been 
lost to follow up..." 
Unclear Low risk 
 
Groups similar at 
baseline, ITT 
Stopped early as 
unethical to 
continue. 
Unclear 
4 Dutch TIA [49] 
Beta blocker 
Low 
Random permuted 
blocks 
Low 
 
Low 
Blinded 
randomisation codes 
were distributed by 
telephone 
Low 
Low risk 
Double blinded - 
patients identical 
placebo appearance 
and taste to active 
tablets. Outcome 
independently 
assessed without 
knowledge of 
Low risk 
No patients lost to 
follow up. ITT 
Low 
 
Low risk 
Low 
 
Low  
Low 
 
Low risk 
Low 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
 treatment allocation.  
Low 
5 EWPHBPE [50, 51] Unclear 
 
Not mentioned 
Low  
 
Individually sealed 
envelope 
Low risk 
 
Triple blinded. 
Numbered drug 
containers so 
doctors, patients and 
outcome 
assessment blind to 
allocation.  
Unclear 
 
128 out of 840 patients 
(15,2%) were lost to 
follow up but unclear if 
even numbers in 
control and treatment 
group.   ITT  
Unclear 
 
Patients were 
censored if they had 
"one of the specific 
study terminating 
events,  
including death, non-
fatal cerebral or 
subarachnoid 
haemorrhage,  
development of 
hypertensive 
retinopathy grade III 
or IV, dissecting  
aneurysm, 
congestive heart 
failure not 
controllable without  
diuretics or 
antihypertensive 
drugs, hypertensive 
encephalopathy,  
severe increase in 
left ventricular 
hypertrophy, and a 
rise in blood  
pressure exceeding 
the defined limits." 
Low risk Unclear 
6 HOPE HYP[52] Low Unclear Low risk Low Unclear Low risk Low risk 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
ACE inhibitors  
Two by two factorial 
randomised 
 
Not mentioned 
 
Double blind and 
Independent 
outcome 
assessment  
 
99.9% of patients 
followed up (9535/9541 
randomised patients) 
 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
reviews 
 
ITT 
7 HSCSG[53] 
High-dose thiazide 
 Unclear Low 
Sealed envelope 
Low risk 
 
Doctor and patient 
blinded and 
independent 
assessment of 
outcomes without 
being aware of 
randomisation 
Unclear 
 
40 patients rejected but 
does not mention 
number lost to follow up 
Unclear 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
reviews 
Low risk Unclear 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
8 HYVET[20] 
Low-dose thiazide 
Low risk 
Permuted blocks of 4 
and 6 of any 10 
patients were used 
to ensure roughly 
equal assignment to 
each of the two 
groups within large 
centres.  
Low 
 
Low risk 
An interactive voice 
response system  
(IVRS) is employed 
to tell the 
investigator which  
6-month drug pack 
to prescribe. 
Unclear 
 
Low risk 
The main trial is a 
randomised, double-
blind,  
placebo-controlled 
trial. “All events that 
were possible end 
points were reviewed 
by an independent 
committee, unaware 
of the group 
assignment, using 
predefined 
definitions from the 
protocol.” 
Unclear 
 
Unclear 
Randomised 1845 
Reported on the 
number of patients lost 
to follow-up (16 
patients) 
 
"...vital status was 
unknown in 17 
patients..." 
High risk 
Unclear 
Cannot extract 
the number of 
patients in each 
group that had a 
non-fatal 
myocardial 
infarctions. 
 
Correspondence 
with the author: 
 
"The serious 
adverse events 
noted in the 
publication...are 
the numbers the 
total serious 
adverse events 
OR was the first 
event counted 
and analyzed? 
Answer: It is the 
total number of 
SAEs. Patients 
could contribute 
more than one 
SAE." 
 
Correspondence 
with the author: 
 
"If a patient had 
an event after 
being censored 
were those 
events counted? 
If not, is it 
possible to see 
that data? 
Answer: It 
would depend 
on the event. If 
Low risk 
ITT 
High risk 
Unclear 
High risk 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
it was a 
recurrent 
endpoint then it 
was not counted 
(e.g. a further 
non-fatal stoke). 
If the event was 
a new endpoint 
(e.g. a fatal MI in 
someone who 
had previously 
had a non-fatal 
stroke) then it 
was." 
 
Unclear 
 
  
9 HYVETpilot [54] 
Low-dose thiazide 
 
ACE inhibitors 
Low risk 
 
"The unit of 
randomization was 
the individual and 
the SAS Random 
Allocation of 
Treatments 
Balanced in Blocks 
Program was used 
to generate the 
schedule." 
High risk High risk 
 
No blinding – open 
design 
Low risk 
 
"Of the 1283 patients 
who were assigned to 
groups, only 27 (2.1%) 
were lost  
to follow-up (had no 
end-of-trial 
information)." 
 
"Of the 426 patients 
allocated randomly to a 
diuretic-based 
treatment, 385 (88.5%) 
were alive and 
provided information at 
the end of the trial. The 
corresponding 
numbers were 397 
(89.8%) for ACE based 
treatment and 394 
Low risk 
 
As this was an open 
study, the 
randomized 
treatment could be 
continued after a 
non-fatal event." 
Unclear Unclear 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
(90.1%) for no 
treatment." 
10 MRC-O[55] 
Low-dose thiazide 
 
Beta-blocker 
 
 
Low risk 
 
Randomisation was 
in stratified blocks of 
eight within each sex 
and clinic.  
Unclear 
 
Methods not 
adequately 
described 
Low risk 
 
Patients blinded, but 
providers not 
blinded. Blind 
outcome 
assessment 
High risk 
 
Loss to follow-up 
(25%). Missing data 
may be due to side 
effects. Beta blocker 
more than diuretic for 
major side effects and 
inadequate BP control. 
No imputations. 
Low risk 
 
All outcomes were 
reported as stated in 
the protocol. 
Unclear risk 
 
Other 
antihypertensive 
drugs added to 
randomly allocated 
treatment to control 
blood pressure. The 
observed effects 
may equally have 
resulted from the 
different additional 
drugs. 
Unclear 
11 MRC-TMH [56] 
High-dose thiazide 
 
Beta-blockers 
Low risk 
 
Stratified blocks of 8 
within each sex, 10 
year age group and 
clinic 
Unclear 
 
No information in the 
text 
Low risk 
 
Doctors not blind, 
only patients, blind 
outcome 
assessment. 
Unclear 
 
19% lost to follow up 
Unclear Low risk 
 
Groups similar at 
baseline, ITT 
Unclear 
12 Oslo [57] 
High-dose thiazide 
 
Low risk 
 
Random numbers 
table  
Unclear 
 
No information 
Unclear 
 
Blind outcome 
assessment by two 
independent 
cardiologists. No 
statement by authors 
Low risk 
 
None lost to follow up 
Unclear 
 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
Low risk 
 
No difference 
between groups,  
Unclear 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
that patients and 
doctors not blinding 
and if they perceived 
this had an effect. 
reviews 
13  PATS [58] 
Low-dose thiazide 
 
Unclear 
 
“patients entered into 
active or placebo 
group according to 
order of envelopes” 
– unclear how that 
order was created. 
 
Low risk  
 
Ordered sealed 
envelope system 
Low risk 
 
Double blind 
 
Unclear 
 
No difference in 
numbers who dropped 
out in placebo and 
active groups due to 
non-medical reasons 
not clear if these 
people were followed 
up but states “patients 
withdrawn from the 
trials were followed up 
to make an intention to 
treat analysis 
 
Unclear 
 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
reviews 
Low risk 
 
No difference in 
patients at baseline, 
ITT 
Unclear 
14 SHEP[59, 60] 
Low dose thiazide 
Low risk 
 
Blocked 
randomisation 
Low risk 
 
"Each randomization 
was carried out by 
telephone" 
Low risk 
 
Described as 
double-blind and 
outcome 
assessment also 
blinded 
Low risk 
 
"We specified an 
“intention to treat” rule 
(with study groups 
divided by the 
randomized 
assignment regardless  
of subsequent 
crossovers) and a plan 
for replacing any  
Unclear 
 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
reviews 
Low risk 
 
ITT 
Low risk 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
missing annual visit BP 
with the last available 
value 
15 SHEP-P [61] 
Low dose Thiazide 
Unclear 
 
No information 
Unclear 
 
No information  
Low risk 
 
Double blind. 
Outcome 
assessment also 
blinded. 
Unclear 
 
No information 
High risk 
 
"For any participant 
who had two or more 
events, one was 
designated the study 
event based on a 
hierarchical 
classification headed 
by death followed by 
four categories of 
nonfatal events in 
rank order of stroke, 
other hypertensive 
events, 
atherosclerotic 
events, and 
noncardiovascular 
events. When there 
were two events in 
one category, the 
event that occurred 
first was used." 
Low risk 
 
ITT and no 
difference at 
baseline 
Unclear 
16 SYST-EUR [62] 
Calcium Channel 
Blockers 
Low risk 
 
"randomized to 
double-blind 
treatment with active 
medication or 
Unclear 
 
No information 
Low risk 
 
Double blind and 
blinded outcome 
assessment 
Low risk 
 
"For patients who 
withdrew from  
treatment for whom 
regular follow-up was 
Unclear 
 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
Low risk 
 
ITT and no 
difference at 
baseline 
Low risk 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
placebo by means of 
a computerized 
random function" 
 not possible, we  
annually collected 
information on vital 
status, occurrence of 
major  
endpoints and other 
events, and the use of 
antihypertensive  
medications (non-
supervised open 
follow-up). Patients 
without  
any report within the 
year before the trial 
stopped were counted 
as  lost to follow-up." 
reviews 
17 TEST [21] 
Beta blockers 
Low risk 
 
Computer generated 
random scheme 
using a random 
permutated block 
design with a block 
size of four was used 
for randomisation, 
stratified for centre, 
age and 
Scandinavian 
treatment score.  
Unclear 
 
No information 
Low risk 
 
Double blind. 
Independent end-
point committee 
reviewed fatal end-
point. 
Low risk 
 
Treatment 
discontinued in 10% 
and all patients 
followed up regardless 
of withdrawal or not.   
Unclear 
 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
reviews 
Low risk 
 
No difference in 
patients at baseline, 
ITT 
Unclear 
18 UKPDS 39[63] 
Beta blocker 
Low risk 
 
Computer-generated 
Low risk 
 
“Allocation 
High risk 
 
Patients not blinded; 
Unclear 
 
Not indicated whether 
Low risk 
 
All outcomes were 
Unclear 
 
Other 
Unclear 
 
 
85 
 
Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
 
ACE Inhibitors 
 
random sequence 
but not blocked so 
slight difference in 
numbers of patients 
allocated to 
treatments.  
concealment was 
done with opaque, 
sealed envelopes 
with a check 
maintained on 
numerical sequence, 
until dates of 
opening and results” 
 
providers not 
blinded. There was 
no blinding of 
outcome 
assessment, but the 
outcome assessed 
(i.e. death) is unlikely 
to be influenced by 
lack of blinding. 
reasons for missing 
outcome data were 
similar across 
treatment groups 
reported as stated in 
protocol. 
antihypertensive 
drugs added to 
randomly allocated 
treatment to control 
blood pressure. The 
observed effects 
may equally have 
resulted from the 
different additional 
drugs. 
19 USPHSHCSG [64] 
High dose thiazide 
Unclear 
 
No information 
Unclear 
 
No information 
Unclear 
 
Double blind, no 
information on 
outcome 
assessment 
High risk 
 
Dropouts 132 (33.9%) 
of whom 75 have been 
lost to regular follow up 
(~17%), vital status of 
26 of dropouts is 
unknown. No 
differential drop out 
rate between treatment 
and control groups and 
similar lack of vital 
status for both groups.) 
Unclear 
 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
reviews 
 
High risk 
 
Per treatment 
analysis, similar at 
baseline. 
High risk 
20 VA-1[65] 
High dose thiazide 
Low risk 
 
Table of active 
numbers  
Low risk 
 
Sealed envelope 
used to assign 
randomisation to 
active 
antihypertensive 
medication or 
Low risk 
 
Double blind. 
Unclear how 
outcome 
assessment was 
carried out. 
Low risk 
 
Total number of drop 
outs 12 out of 143 or 
8.4%. Divided equally 
between placebo and 
active patients.  
Unclear 
 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
reviews 
Low risk 
 
Similar at 
baseline.no 
statistically 
significant 
differences. 
Low risk 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
placebo  ITT 
21 VA-11 [66] 
High dose thiazide 
Low risk 
 
Table of active 
numbers 
Low risk 
 
Sealed envelope 
used to assign 
randomisation to 
active 
antihypertensive 
medication or 
placebo 
Low risk 
 
Double blind. 
Unclear how 
outcome 
assessment was 
carried out. 
Unclear 
 
Total number of drop 
outs 56 out of 380 or 
15%. Divided equally 
between placebo and 
active patients but 
don’t know reason for 
24. Possible that 
reason for missing 
outcome data may be 
related to true outcome 
as 3 of the patients in 
placebo group non-
terminating morbid 
events prior to their 
dropping out.  
Unclear 
 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
reviews 
Unclear 
 
Similar at 
baseline.no 
statistically 
significant 
differences. Not ITT.  
Unclear 
22 VA-NHLBI[67] 
High dose thiazide 
Unclear 
 
Randomisation by 
next unused therapy 
number from a list 
supplied by the data 
centre 
Low risk 
 
Drugs unique 
therapy number 
Low risk 
 
Double blind. 
Outcome 
assessment may be 
blinded but unclear. 
High risk 
 
Total number of drop 
outs 98/508 (19%) 
active group and 
104/504 (21%) placebo 
group. 
Unclear 
 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
reviews 
Unclear  
 
Not clear if groups 
similar at baseline 
Unclear 
23 Wolff [22] Low risk 
 
Low risk 
 
Low risk 
 
Low risk 
 
Unclear 
 
Low risk  
 
Low risk 
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Trial Study Sequence 
Generation  
Allocation 
Concealment 
Blinding Incomplete 
outcome data 
Selective 
outcome 
reporting 
Other sources 
bias 
Overall Risk of 
Bias 
High dose thiazide 
 
Table of random 
numbers 
Coded drugs Double blind. 
Outcome 
assessment may be 
blinded but .unclear 
10 patients in drug 
group and 1 in placebo 
group absent and 
stopped attending 
clinic. ie 6 out of 10 
followed up by nurses 
and “delinquent for 
social rather than 
medical reasons. None 
admitted any increase 
in symptoms 
suggested of treatment 
failure.” 
No protocol available 
and no duplicate 
data extraction in 
previous Cochrane 
reviews 
Appear similar at 
baseline of groups. 
Results for all 87 
patients presented, 
ITT 
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Table 8.4 with PRECIS-2 scores for each domain in HYVET [21] - Treatment of Hypertension in Patients 80 years of age or older (more 
explanatory trial) 
 Domain Score Rationale 
1 Eligibility Criteria 1 Not usual care – focussing on older people - those 80 years of age or older and had a sustained 
systolic blood pressure of 160mm Hg or more. Often this group though is excluded from clinical 
trials. (Checked pre-trial by stopping all hypertensive treatments for at least TWO months and 2 
blood pressure measurements during 2 visits, 1 month apart, after having been seated for 5 
minutes. Third visit, standing blood pressure taken twice after patient standing for 2 minutes). 
Exclusion criteria included a contraindication to use of the trial medications, accelerated 
hypertension, secondary hypertension, hemorrhagic stroke in the previous 6 months, heart 
failure requiring treatment with antihypertensive medication, a serum creatinine level greater 
than 150 μmol per liter (1.7 mg per deciliter), a serum potassium level of less than 3.5 mmol 
per liter or more than 5.5 mmol per liter, gout, a diagnosis of clinical dementia, and a 
requirement of nursing care. In usual care antihypertensives can be used by all ages – usually 
over 40.  
2 Recruitment Path 3 Unclear but also had placebo run in period. 
3 Setting 5 195 centres, in 13 countries in Europe, China, Australasia,  and North Africa 
4 Organisation intervention 3 Unclear - no specific mention of resources, expertise, organisation. There were issues with 
some centres having to be dropped as incomplete data or failure to use validated equipment or 
inadequate data. 
5 Flex of experimental intervention – 
Delivery 
2 Investigators could adjust the dose of the trial medication more frequently than at each visit, if 
desired so tailored to individual patients’s needs. Patients received either indapamide 
(sustained release, 1.5 mg) or matching placebo alone. At each visit (or at the discretion of the 
investigator), if needed to reach the target blood pressure for the individuals, perindopril (2 mg 
or 4 mg) or matching placebo could be added. The target systolic blood pressure was less than 
150 mm Hg, and the target diastolic blood pressure was less than 80 mm Hg. The use of 
additional antihypertensive agents for more than 3 months resulted in withdrawal of the 
patient from double-blind follow-up, with an option to enter open follow-up. Patients were also 
withdrawn from double-blind treatment if they had received the maximum dose of the study 
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drugs yet had a systolic blood pressure while sitting of 220 mm Hg or more or if they had a 
diastolic blood pressure while sitting of 110 mm Hg or more on at least two consecutive visits 
that were 2 or more weeks apart. 
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6 Flex of experimental intervention – 
Adherence 
2 Run-in period so exclude non-compliers thereafter does not appear to be exclusion based on 
compliance. Exclusion if blood pressure too high after 3 months or if had additional 
hypertensives for more than 3 months. 
7 Follow up 1/2  Every 3 months during 1st year and at least every 6 months thereafter BP measured, for the 
trial period (6.5 years before terminated for ethical reasons) -10,500 patient years planned. 
Extensive data collection, far more than usual care which would be BP and blood tests. ECG 
only done in usual care if indicated as is cognitive function. Annual visits: information was 
collected on current diseases, medication, blood pressure, biochemical levels (sodium, 
potassium, urea, creatinine, glucose, uric acid, cholesterol levels (total and high-density 
lipoprotein), and hematologic measures (hemoglobin, hematocrit), and electrocardiography 
and an assessment of cognitive function with the use of the Mini–Mental State Examination 
were performed. If the patient was enrolled in an optional add-on study, a quality-of-life 
questionnaire was also completed. At the 3-month and 6-month visits, only data on current 
diseases, medication, and blood pressure were collected. Had to come out of trial double blind 
follow up if on additional treatment for hypertension for more than 3 months but could 
continue with open follow up. 
8 Primary Outcome 3 Fatal or nonfatal stroke and centrally adjudicated. Of interest to patient but of greater interest 
would probably have been the secondary outcome “Death from any cause”.  
9 Analysis 5 ITT but also per protocol analysis 
 
Table 8.5 with PRECIS-2 scores for each domain in WOLFF  [22]- Effects of Treatment on Morbidity in  Hypertension (more pragmatic trial) 
 Domain Score Rationale 
1 Eligibility Criteria 4 Male and female patients, mainly black, with a diastolic BP of 100 mm Hg or more (3 separate 
occasions at least one week apart) after resting for 5 mins on a bed. Usual exclusions but not 
people already taking antihypertensives or those who have cardiovascular disease 
2 Recruitment Path 3 Appears to referral to clinic but unclear 
3 Setting 3 One setting but usual setting for treatment of high blood pressure - Baltimore City hospitals, 
USA one hypertension clinic 
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4 Organisation intervention 5 No additional personnel or resources or training mentioned 
5 Flex of experimental intervention – 
Delivery 
5 Flexible focussing on individual patient’s cardiovascular symptoms. Keep regime for 3 months 
before changing.  
6 Flex of experimental intervention – 
Adherence 
5 Does not appear to be monitored or part of treatment 
7 Follow up 5 Up to 2 years - Successive visits until stabilised, CXR and ECG every 6 months, blood, glucose 
levels, 3 months. Eyes and urine test, blood test every clinic visit. Routine examinations 2 month 
intervals but could be 1 week to 5 month intervals so appears that follow up based on individual 
patients.  
8 Outcome 2 Composite outcomes – many symptomatic so patient relevant outcomes. Treatment failure eg 
cardiovascular accident, headache, coronary artery disease, congestive heart failure, 
retinopathy, clinical diabetes, deaths, increasing serum urea nitrogen and proteinuria – latter 
very explanatory. 
9 Analysis 5 Results for 87 patients presented and all reasons for treatment failures, relatively small 
numbers and composite outcomes presented, 10 absentees in drug group but 6 out o 10 
followed up by nurses and “delinquent for social rather than medical reasons. None admitted 
any increase in symptoms suggestive of treatment failure.” 
 
 
Table 8.6 23 trials in Cochrane review for internal and external validity 
Duplicate entry ST four trials 
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 Study Pragmatic/ 
Explanatory  
Effect size  
Risk Ratio 
Fixed, 95% CI 
Risk of   Bias 
(Allocation 
concealment) 
Intervention Outcome PRECIS-2 wheel 
1 ATTMH [176] 
High-dose 
thiazide 
Explanatory 
Hard to say 
 
Total mortality 
0.71 (0.43-
1.18) 
 
High 
Unclear 
 
Chlorothiazide 500 
mg, 1000 mg,  
Methyldopa, 
propranolol, or 
pindolol,  
Hydralazine or 
clonidine 
mortality, stroke, CHD, 
CHF (patients were 
censored after the first 
outcome so data is 
limited to first outcome 
in each category) 
 
ST 
“wheel”
 
2 Barraclough 
[172] 
High-dose 
thiazide  
Explanatory 
Explanatory 
 
 
Total mortality 
0.33 (0.04-
3.11) 
High 
High 
Bendrofluazide 
(93%), Methlydopa, 
and debrisoquine 
mortality, CHD, stroke, 
CHF, and diastolic BP 
 
ST “wheel” 
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3 Carter [200] 
High-dose 
thiazide 
pragmatic Total 
mortality:0.58 
(0.33-1.01) 
Unclear Thiazide, 76%, 
Methyldopa (0.75-
2 g), bethanidine or 
debrisoquine 
Stroke, mortality, CHD, 
CHF 
  
  
4 Dutch TIA [201] 
Beta blocker  
pragmatic Total mortality 
1.12 (0.79-
1.57) 
Low 
Low 
Atenolol 50 mg 
daily  
Identical placebo 
tablet 
Mortality, CHD, stroke, 
total CV events, 
 
ST “wheel” 
 
5 EWPHBPE [202, 
203] 
explanatory Total mortality 
0.92 (0.76-
1.12) 
Unclear HCTZ/triamterene, 
25/50 mg. 1 to 2 
tabs, methyldopa 
0.5-2 g. 
Mortality, stroke, CHD, 
CHF, systolic BP and 
diastolic BP 
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6 HOPE HYP 
[204] 
ACE inhibitors 
explanatory Total mortality 
0.79 (0.67-
0.93) 
Low Ramipril 2.5 mg 
titrating up to 10 
mg or placebo. 
Other factor was 
Vitamin E 400 
IU/day. 
Primary: composite of 
myocardial infarction, 
stroke, or cardiovascular 
death (total CV events).  
Total mortality, total 
stroke, total CHD. 
 
7 HSCSG [205] 
High-dose 
thiazide 
explanatory Total mortality: 
1.01 (0.6-1.72) 
Unclear Deserpidine 1 mg 
plus 
methyclothiazide 
10 mg. 
Mortality, stroke, CHD, 
CHF, systolic BP and 
diastolic BP 
 
8 HYVET [174] 
Low-dose 
thiazide 
explanatory Total mortality 
0.82 (0.69-
0.99) 
Low 
 
Step 1 indapamide 
1.5 mg daily. Step 2 
perinodopril 2 mg 
daily. Step 3 
perindopril 4 mg 
daily.  
Control: identical 
appearing placebos 
for each step 
Total stroke, total 
coronary artery disease, 
total mortality, total 
cardiovascular events 
(including CHF)  
9 HYVETpilot  
[206] 
Low-dose 
thiazide 
pragmatic Total mortality 
1.29 (0.77-
2.16) 
 
1.11 (0.65-
Unclear 
Unclear 
Diuretic (usually 
bendrofluazide 2.5 
mg), an ACE 
inhibitor (usually 
lisinopril 2.5 mg) or 
Total stroke, total 
mortality, cardiovascular 
mortality, cardiac 
mortality, sitting systolic 
BP and diastolic BP.  
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ACE inhibitors 
1.90) no treatment.  ST  “wheel” 
10 MRC-O [207] 
Low-dose 
thiazide 
 
Beta-blocker 
 
 
explanatory Total mortality 
0.87 (0.72 – 
1.05) 
 
1.06 (0.90-
1.27) 
Unclear HCTZ/amiloride, 25 
mg/2.5 mg , 
atenolol 50 mg 
daily, or placebo 
Mortality, Stroke, CHD, 
systolic BP and diastolic 
BP 
 
11 MRC-TMH 
[208] 
High-dose 
thiazide 
 
Beta-blockers 
Pragmatic Total mortality 
1.02 (0.83 – 
1.26) 
 
 
0.93 (0.75-
1.15) 
Unclear Bendrofluazide 10 
mg daily (71% 
mono) , 
Propranolol 80-240 
mg daily (78% 
mono) , 
methyldopa added 
if required. 
Mortality, stroke, CHD, 
systolic BP and diastolic 
BP. 
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12 Oslo [209] 
High-dose 
thiazide 
 
Explanatory Total mortality 
1.04 (0.43 – 
2.52) 
Unclear Hydrochlorothiazid
e (95%), 
methyldopa, and 
propranolol (26%).  
Stroke, CHD, mortality, 
CHF, systolic BP and 
diastolic BP 
 
13  PATS [210] 
Low-dose 
thiazide 
 
pragmatic Total mortality 
0.92 (0.74-
1.14) 
Unclear Indapamide 2.5 mg 
daily  
Identical placebo 
tablet 
Mortality, stroke, 
coronary heart disease, 
blood pressure 
 
14 SHEP[211, 212] 
Low dose 
thiazide  
explanatory Total mortality 
0.88 (0.74 – 
1.05) 
Low risk Chlorthalidone 
12.5-25 mg (69%), 
Step 2. atenolol 25-
50 mg (23%) or 
reserpine 0.05-0.1 
mg.  
Identical placebo. 
Mortality, stroke, CHD, 
CHF, systolic BP and 
diastolic BP 
 
15 SHEP-P [213] 
Low dose 
Thiazide 
explanatory Total mortality 
1.11 (0.51-
2.46) 
Unclear Chlorthalidone 25-
50 mg daily (87%) 
Step II randomised 
to hydralazine, 
reserpine or 
metoprolol (13%). 
Mortality, CHD, stroke, 
CHF, systolic BP and 
diastolic BP 
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16 SYST-EUR [214] 
Calcium 
Channel 
Blockers 
Pragmatic  Total mortality 
0.86 (0.68-
1.09) 
Low risk Nitrendipine, 10 
mg daily, 10 mg 
BID, 20 mg BID, 
enalapril 5mg, 10 
mg, 20 mg daily in 
evening, HCTZ 12.5 
mg, 25 mg daily in 
morning. Matched 
placebos 
mortality, stroke, CHD, 
CHF, systolic BP and 
diastolic BP. 
 
17 TEST [173] 
Beta blockers 
Pragmatic Total mortality 
0.80 (0.56 -
1.12)  
Unclear Atenolol 50 mg 
daily  
Identical placebo 
tablet 
Mortality, stroke, CHD, 
hospitalizations, BP 
 
18 UKPDS 39[215] 
Beta blocker 
 
ACE Inhibitors 
 
Explanatory Total mortality 
0.77 (0.57-
1.05) 
 
 0.88 (0.67-
1.16) 
Unclear Tight BP control 
group (Captopril 
25mg -50mg b.i.d. 
or atenolol 50mg 
o.d. to 100 mg/day.  
mortality, stroke, CHD 
and CHF, systolic BP and 
diastolic BP 
 
19 USPHSHCSG 
[216] 
High dose 
thiazide 
explanatory Total mortality 
0.51 (0.09-
2.74) 
High Chlorothiazide 500 
mg BID plus 
rauwolfia 
serpentina 100 mg 
Mortality, CHD, stroke, 
CHF, systolic BP and 
diastolic BP 
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BID versus placebo 
20 VA-1[217] 
High dose 
thiazide 
explanatory Total mortality 
0.11 (0.01 – 
1.94) 
Low risk step 1. HCTZ 100 
mg plus reserpine 
0.2 mg plus 
hydralazine 75 mg.  
step 2 hydralazine 
150 mg. 
Mortality, stroke, CHD, 
CHF, and diastolic BP 
 
21 VA-11 [218] 
High dose 
thiazide 
explanatory Total mortality 
0.50 (0.24 – 
1.03) 
Unclear step 1. HCTZ 100 
mg plus reserpine 
0.2 mg.  
step 2. hydralazine 
75-150 mg 
Mortality, CHD, stroke, 
CHF, systolic BP and 
diastolic BP 
 
22 VA-NHLBI[219] 
High dose 
thiazide 
explanatory Total mortality 
4.96 (0.24 – 
103.07) 
Low risk CHTD 50 mg, 100 
mg, (53% CHTD 
alone)  
Reserpine 0.25 mg 
Mortality, stroke, CHD, 
CHF, and diastolic BP 
 
23 Wolff [175] 
High dose 
thiazide 
 
pragmatic Total mortality 
1.87 (0.36 – 
9.67) 
Low risk reserpine 0.25 mg 
TID, chlorthiazide 
0.5 g BID, or HCTZ 
25 mg QID plus 
guanethidine if 
needed 
Mortality, stroke, MI, 
CHF, systolic BP and 
diastolic BP 
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Chapter 9: APT: Applying PRECIS-2 to Primary Care Trials Pilot and two Case 
studies 
 
Figure 9.1 questionnaire for trial teams using PRECIS-2 to discuss trial design (Designed by 
GF with suggestions from APT Study Steering group) 
 
APT Study: Feedback Questionnaire 
Thank you for taking part in the APT study. We hope you enjoyed the session and found the tool, 
PRECIS-2, useful. Please could you complete the following feedback questionnaire. 
Name of  
trial: 
  
 
Role in trial team: 
  
 
1. The online training material contained sufficient information about PRECIS-2  
Strongly 
Agree 
 Neither agree or 
disagree 
 Strongly 
disagree 
5 4 3 2 1 
 
2. The online information on how to use the tool is clear and concise  
Strongly 
Agree 
 Neither agree or 
disagree 
 Strongly 
disagree 
5 4 3 2 1 
 
3. The online tool is easy to use 
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Strongly 
Agree 
 Neither agree or 
disagree 
 Strongly 
disagree 
5 4 3 2 1 
 
 
4.  PRECIS-2 would have been useful to use in the design stage of the trial 
 
Strongly 
Agree 
 Neither agree or 
disagree 
 Strongly 
disagree 
5 4 3 2 1 
 
5. Meeting to discuss independent scores lead to more accurate scores being  produced than 
were produced independently 
 
Strongly 
Agree 
 Neither agree or 
disagree 
 Strongly 
disagree 
5 4 3 2 1 
 
6. PRECIS-2 highlights areas of trial design which are important for your trial to achieve its 
goals, be that informing clinical decision making or increasing knowledge of how an 
intervention works. 
Strongly 
Agree 
 Neither agree or 
disagree 
 Strongly 
disagree 
5 4 3 2 1 
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7. How important do you think each of the PRECIS-2 domains is in ensuring the results from 
your trial are relevant to their intended audience 
 
i. Eligibility - Who is selected to participate in the trial? 
Very 
Important 
   Not at all 
Important 
5 4 3 2 1 
 
ii. Recruitment - How are participants recruited into the trial? 
Very 
Important 
   Not at all 
Important 
5 4 3 2 1 
iii. Setting - Where is the trial being done? 
Very 
Important 
   Not at all 
Important 
5 4 3 2 1 
 
iv. Organisation – What expertise and resources are needed to deliver the 
intervention? 
Very 
Important 
   Not at all 
Important 
5 4 3 2 1 
 
v. Flexibility - How should the intervention be delivered? 
Very    Not at all 
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Important Important 
5 4 3 2 1 
 
vi. Flexibility - What measures are in place to make sure participants 
adhere to the intervention? 
Very 
Important 
   Not at all 
Important 
5 4 3 2 1 
 
vii. Follow-up - How closely are participants followed-up? 
Very 
Important 
   Not at all 
Important 
5 4 3 2 1 
 
viii. Primary outcome -How relevant is it to participants? 
Very 
Important 
   Not at all 
Important 
5 4 3 2 1 
     
ix. Primary analysis - To what extent are all data included? 
Very 
Important 
   Not at all 
Important 
5 4 3 2 1 
     
Additional comments for the APT study team 
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